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ABSTRACT
The discovery and therapeutic development of the anticancer drug cisplatin
was an important milestone in the treatment of people suffering from many
tumours, especially teratoma and ovarian carcinoma. The main problem
with the drug is its toxicity which necessitated the development of similarly
active but better tolerated analogues, for example carboplatin. Despite
demonstrating a more acceptable toxicity profile, carboplatin and other
newer platinum chemotherapies are not ideal drugs both because of their
side-effects and also because tumours may demonstrate primary or acquired
platinum resistance.
In order to understand better the mechanisms by which tumours become
resistant to platinum chemotherapy, tumour models have been developed for
in vitro experiments. Some of these tumours are murine, but there is an
increasing library of human tumour types which allow measurement of
various cellular activities and enzymes believed to be relevant in drug
resistance.
In this thesis, the results are presented of experiments performed to
investigate the mechanisms of platinum resistance in the murine L1210
leukaemia cell line in vitro. In addition, platinum resistant L1210 variants
have been developed and these cell lines are also studied.
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In addition to allowing characterisation of the resistant cells, murine and
human tumour models are invaluable in screening novel compounds for
antitumour activity. In the second part of the thesis, the L1210 sensitive
and resistant cell lines are employed along with human ovarian cancer cell
lines in vitro to screen several compounds which are structurally related to
the parent platinum drugs cisplatin, carboplatin, tetraplatin and iproplatin.
The aim of the work was to identify compounds which demonstrated
cytotoxic activity against cell lines which were known to be platinum
resistant. The mixed amine platinum IV dichlorodicarboxylates were
selected and data on their in vitro activities are presented. The six leading
novel compounds were also tested for relative activity against the
plasmacytoma tumour ADJ/PC6 in murine xenografts, and their relative
activities and toxicities when delivered by the oral or the intraperitoneal
route were investigated.
Finally, the pharmacokinetic profiles of the six lead compounds were studied
in non-tumour bearing mice following oral delivery. The haematological
toxicities are also presented from experiments in the murine model.
On completion of the initial studies detailed in this thesis, further
experiments have resulted in selection of one of the six compounds, JM21 6,
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1.1 Cisplatin: Discovery and mode of action.
In 1 965 Rosenberg reported in "Nature" [Rosenberg et al, 1 965] that during
investigation of the effects of an electric field on the growth processes in
bacteria, his team discovered that within 1-2 hours of passing an electric
current of 2 amp between platinum electrodes, E. coli bacteria ceased
dividing and began to elongate. Within a few hours, all of the bacteria were
in the form of elongated filaments with the increase in length continuing for
two hours after removal of the voltage. Further study of the cause of the
filamentous growth (defined as inhibition of cell division but not of growth)
revealed that a platinum salt was the active agent, since inoculating the
bacterial continuous culture chamber with a solution of (NH4)2PtCI6 so as to
maintain a concentration in the chamber of Pt(IV) 10ppm over 2 hours
caused filaments to appear. More detailed investigation into the properties
of one of the platinum-derived species revealed that the compound cis-
platinum II diamminodichloride (cisplatin - structure shown in Figure 1.1) had
significant growth inhibition effects on several transplantable rodent
tumours, including the L1210 murine leukaemia, sarcoma 180 [Rosenberg
and von Camp, 1970] Dunning ascitic leukaemia and Walker 256
carcinosarcoma [Kociba et al, 1970]. It was, therefore, only a matter of
time until cisplatin was brought to clinical trials as a prospective
antineoplastic drug.





FIGURE 1.2 CIS AND TRANS-PLATINUM STRUCTURES
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Prior to its introduction to the clinic in 1971, the mechanism of action of
cisplatin was poorly understood. Subsequently it has been established that
in aqueous solution, both chlorine atoms are slowly displaced with water
leading to the formation of a positively charged aquated complex [Leroy et
a[, 1979]. The activated complex then interacts with nucleophilic sites on
DNA purine and pyrimidine bases to produce bifunctional covalent links
[Zwelling and Kohn, 1979]. The end result is very similar to the effect
produced by the alkylating antitumour drugs chlorambucil and melphalan.
Further analysis identified the specific sites of action to be the N7 of guanine
or the N3 of cytosine residues. The major adducts are intrastrand cross links
formed by the binding of cisplatin to two neighbouring guanines or, less
frequently, to adenine and guanine or to two guanines separated by one or
more nucleobases [Roberts and Thomson, 1 979; Zwelling and Kohn, 1979].
Interstrand cross-links between two guanines on complementary DNA
strands, and DNA protein cross-links are also formed. Experiments were
carried out to determine the importance of the position of the ammine and
the chloride groups. The conclusion was that cis- compounds (Figure 1.2)
were more effective than trans- compounds at inducing interstrand cross¬
links in DNA and could more readily induce links between adjacent guanines
on the same strand of DNA [Roberts and Friedlos, 1987]. It has been
established that the interstrand cross links account for less than 1 % of all
cross links, and this suggests that the intrastrand links are the more
significant of the two [Eastman, 1983; Pascoe and Roberts, 1974].
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Studies on the excision repair of platinum adducts on the DNA of various
cell types confirmed that DNA is the target for the cytotoxic action of
cisplatin. Cells which were exposed to cisplatin while in stationary phase
and immediately diluted into fresh complete medium to release them from
the stationary phase were more sensitive to cisplatin than were cells treated
while in the exponential phase of growth. A reduction in excision repair
capacity was the reason for the increased sensitivity, as demonstrated by
the finding that excision-proficientexponentially growing cells removed more
DNA-bound platinum prior to replication of their DNA than did stationary
cells [Fraval and Roberts 1 979]. This strongly supports the contention that
it is the platinum bound to the DNA at initiation of DNA replication which
determines cytotoxicity. Further, repair defective xeroderma pigmentosum
cells are significantly more sensitive to cisplatin than are other cell lines.
The changes in DNA conformation induced by cisplatin result in inhibition of
DNA synthesis thereby inducing a delay in the cells' progression through the
S (DNA synthesis) phase. The toxic effect of cisplatin is therefore maximal
when cells are treated at the intermitotic or G1 phase of the cell cycle
[Fraval and Roberts, 1979].
It has been suggested that cisplatin can increase the naturally occurring cell-
mediated lysis of tumour cells through increasing the tumour cell surface-
associated antigens which permit the immunological recognition and
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subsequent rejection of cisplatin-treated cells. The phenomenon was
demonstrated in murine and in human tumour cells [Collins and Kao, 1 989]
and since it was shown that the lysis was performed by naturally occurring
cytotoxic cells, the postulate is that these cells may provide a host defence
mechanism which contributes to the anticancer potential of cisplatin.
1.1a Clinical activity.
Phase I trials with cisplatin were encouraging in that responses were seen
in a variety of tumours including anaplastic thyroid carcinoma (1 patient),
transitional cell carcinoma of the bladder (1 patient), breast cancer (1
patient) and testicular tumours (9 of 11 patients). The fact that three of the
responses were complete (ie. no measurable tumour was seen after
treatment) was the most exciting finding, and raised hopes that the platinum
based drug might have a specific effect on tumours arising from the
genitourinary tract [Hiqbv et al, 1974].
Further trials with cisplatin confirmed its impressive efficacy in testicular
tumours [Hiqbv et al, 1973] and advanced ovarian cancer [Wiltshaw and
Kroner, 1976]. Cisplatin was shown to have low single-agent activity in
patients with lung cancer with only one response in an adenocarcinoma from
a trial population of 17 patients when 75mg/m2 cisplatin was given 3
weekly [Rossof et al, 1976], Although cisplatin has a single agent activity
of 30% in advanced urothelial tumours [Yagoda, 1983], it is now used
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mainly in combination with other antineoplastic drugs - for example the
curative combination of bleomycin, etoposide and cisplatin (BEP) in testicular
tumours [Peckham, 1983].
Alternative routes of delivery of cisplatin have been explored in an attempt
to ensure maximum concentration of drug at the site of the tumour without
associated toxicity to normal surrounding tissues. Intraperitoneal
administration of cisplatin as treatment for malignant mesothelioma was
found to produce responses in 9 of 13 patients who had primary peritoneal
disease. Of 8 patients treated for primary pleural disease, only 1 responded.
Cisplatin was given at weekly doses of 90-100mg/m2 with simultaneous
intravenous administration of sodium thiosulphate as renal protection (see
1.1 d) and was no more toxic than delivery by the intravenous route
[Markman et al, 1986]. In a pilot study treating gastric cancer, adjuvant
intraperitoneal cisplatin 60mg/m2 was given to 18 patients. Radioisotope
tracer studies in 6 patients confirmed good drug distribution throughout the
peritoneal cavity. There was no WHO Grade 11 l/l V toxicity and the median
survival was 17 months [Jones et al. 1994]. Cisplatin has also been
administered by intra-arterial injection in primary hepatocellular carcinoma
with responses seen in 4 of 10 patients using relatively low doses of
50mg/m2 [Kajanti et al, 1986]. In head and neck cancer, intra-arterial
administration of cisplatin 10mg twice daily x5-10 days produced good
response rates of 68%, but this was to be expected in a treatment-naiive
23
group of patients where the majority of tumours were squamous cell
carcinomas [Frustaci et al, 1986]. The duration of the responses was not
stated in the paper. Hyperthermic isolated limb perfusion with cisplatin in
patients with advanced malignant melanoma of one leg resulted in complete
responses in 12 of 15 patients in one study where the dose used was
75mg/m2 [Klein and Ben-Ari, 1987]. At a mean follow-up of 36 months,
85% of the patients were alive and disease-free. Cisplatin has even been
given by subconjunctival injection in rabbits which had been implanted with
ocular melanoma in an attempt to penetrate this pharmacological sanctuary
site [Skov et al. 1 987], A report by Deurloo and colleagues commented on
the advantages in delivering cisplatin by a slow-release device [Deurloo et
al, 1991]. Mice were exposed to drug given either by the intraperitoneal
route or by starch or polymeric hydrogels. The slower release formulations
achieved higher total tumour drug concentrations, but there was no
homogeneous distribution of drug within the tumour.
1.1b High dose cisplatin.
In addition to experimenting with compartmental chemotherapy, efforts have
been made to increase the response rate of cisplatin by dose escalation from
standard 20mg/m2 daily for 5 days to 40mg/m2 daily for 5 days. There were
responses in 3 of 6 patients with ovarian cancer whose tumours were
resistant to the conventional dose schedule and with combination therapy
for high risk non-seminomatous testicular carcinoma there was an 88%
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complete response rate [Ozols et al, 1984]. In advanced head and neck
cancer, high dose cisplatin therapy resulted in objective responses in 1 6 of
22 (73%) of patients treated, of whom 11 had recurrent disease. Two of
these were complete responses, one of which was confirmed pathologically
[Forastiere et al, 1987]. Even in metastatic malignant melanoma, a tumour
resistant to most forms of chemotherapy, high dose cisplatin administered
with a normal tissue protecting thiophosphate WR2721 achieved response
rates of 53% although the media*n duration of response was short at 4
months (Glover et al, 1987].
The effect of single agent high dose cisplatin (up to 140mg/m2) in lung
cancer was disappointing, with only 1 of 9 patients with small cell cancer
(SCLC) and none of the 24 patients with non-small cell cancer (NSCLC)
achieving a response [Bhuchar and Lanzotti, 1982], Twenty patients had
received previous chemotherapy and this may have had some bearing on the
poor response rates.
In children with solid tumours, delivery of high dose cisplatin (40mg/m2 daily
x5) by continuous infusion resulted in progressive enhancement of tissue
exposure to the free cytotoxic drug but increased toxicity was experienced
and there was a concomitant decrease in therapeutic effect [Dominici et al,
1989],
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High dose platinum has also been delivered by alternative routes with the
aim of increasing the local tumour concentration of the drug while
minimising the side effects induced in other organs, for example the kidneys.
Intraperitoneal infusion of high dose cisplatin (200mg/m2) with etoposide
and kidney-protecting sodium thiosulphate was given to 37 patients with
ovarian cancer who had failed primary intravenous cisplatin-based treatment.
The overall response rate was 65% and 9/24 patients had a pathological
complete response (CR). Median survival was 26 months from the start of
ip therapy. As primary treatment in 23 patients with stage 11 l/l V ovarian
cancer, the response rate was 14/23 and 43% had a pathological CR at
second-look laparotomy after 6 treatments [Howell et al, 1991].
1.1c Toxicity of cisplatin.
The main problem encountered with cisplatin is the severe toxicity which
continues to limit its clinical use. The frequency of nephrotoxicity is high,
with 61% of courses of cisplatin given at 100mg/m2 associated with acute
renal toxicity [Rossof et al, 1 972]. Subsequently, prehydration and mannitol
diuresis were given before platinum and although the rate of delivery of
cisplatin was 120mg/m2 over 1 5 minutes, a protective effect was observed
[Hayes et al, 1977], The histological changes seen in the kidney after
cisplatin treatment are focal acute tubular necrosis affecting primarily the
distal collecting tubules and collecting ducts. Dilatation of the convoluted
tubules and cast formation are also reported [Gonzales-Vitale et al, 1977].
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The concurrent administration of aminoglycoside antibiotics has been found
to increase the cisplatin-induced nephrotoxicity [Gonzales-Vitale et al. 1 978]
and this combination of drugs should be avoided whenever possible. The
mechanism by which renal toxicity is produced has not yet been fully
elucidated, but is partially due to the known fact that heavy metals induce
passive backflow of glomerular filtrate across the disrupted tubular
epithelium [Hollenberg, 1970]. The brush border of the proximal tubule is
the principal site of toxicity induced by the heavy metals, and reduced
glomerular filtration and renal blood flow to the cortex and the medulla
mediated through the renin-angiotensin system result in acute renal failure
[Madias and Harrington, 1 978]. Increasing the volume of fluid traversing the
renal tubules through mannitol, frusemide and saline diuresis of up to 2 litres
in 6 hours can reduce the nephrotoxicity as explained above [Chary et al,
1 977]. In the high dose cisplatin regimen of Corden and colleagues minimal
nephrotoxicity was seen following 200mg/m2 with 6l/day normal saline
starting from 1 2 hours before starting cisplatin to 24 hours after completion
of treatment [Corden et al, 1985]. With this regimen, the other toxic effects
- detailed below - were at least equivalent to those seen with conventional
cisplatin doses. It was postulated that the high concentration of the chloride
ion in the prehydration fluid helped to protect the luminal cells from damage
through mass action lowering of the reaction rate of cisplatin hydrolysis and
by reducing reactions with tubular sulfhydryl-containing enzymes.
Nephrotoxicity was measured only through estimation of the serum
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creatinine and creatinine clearance in the study and it has since been shown
that these parameters correlate poorly with the glomerular filtration rate
(GFR) during platinum treatment, unlike the 51Cr-EDTA clearance which is
now used [Daugaard et al, 1988].
In a study where the nephrotoxicity of cisplatin in rats was reduced through
delivery of the drug in a liposome carrier system, the antitumour effect of
cisplatin was preserved at a dose of 2mg/kg, but tumour regrowth
developed earlier than it would have done after delivery of free cisplatin
[Steerenberg et al, 1 388]. It would therefore seem that unlike the promising
results obtained for encapsulation of adriamycin and methotrexate,
liposomes are not a satisfactory carrier system for cisplatin.
Nausea and vomiting are other prominent side effects of cisplatin, and they
may be very severe and protracted. These are toxicities which many
patients find most distressing [Coates et al, 1983], and some people refuse
further treatment even with potentially curative treatment because of the
unacceptability of prolonged gastrointestinal upset. Even high doses of
antiemetics such as metoclopramide (2mg/kg by intravenous injection),
although superior in efficacy to phenothiazines and dexamethasone, fail to
alleviate the nausea and vomiting produced by platinum chemotherapy
[Cunningham et al, 1985]. The problems with akathisia and dystonic
reactions experienced by patients who were treated with high dose
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metoclopramide encouraged further research into the mechanisms of nausea
and vomiting, and this resulted in the development of the highly selective 5-
hydroxytryptamine-3 (5-HT3) receptor antagonists which are effective
antiemetics devoid of the adverse effects associated with dopamine receptor
blockade. Initial results of trials with ondansetron, the first selective 5-HT3
receptor antagonist, produced complete or major control in almost two thirds
of platinum induced emesis when given prophylactically and in addition to
the increased efficacy there was reduced toxicity reported by the patients
[Marty et al, 1990]. Since 40% of patients suffer from acute or delayed
vomiting despite use of 5-HT3 antagonists, combination treatment with the
addition of dexamethasone to the antiemetic regimen is recommended to
increase efficacy prior to administration of platinum chemotherapy
[Cunningham et al, 1989].
Bilateral, symmetrical high-tone deafness is also a well recognised side-
effect of cisplatin chemotherapy, and is observed in up to 90% of patients
receiving standard doses of up to 1 20mg/m2 per course [Ellerbv et al, 1974].
When the dose is increased to 200mg/m2, 75% of patients receiving two
courses and 92% who had three courses developed significant hearing loss
with 83% suffering severe damage [Pollera et al, 1988]. The ototoxicity is
most often experienced by people who already have hearing problems
through disease or old age. It is dose-related, cumulative and irreversible
[Helson et al, 1978], and treatment may have to be discontinued if it
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develops. Neither the administration of hypertonic saline nor vigorous
hydration - which are effective in minimising renal toxicity after cisplatin
treatment - have any effect on ototoxicity. Often the earliest indication of
ototoxicity is the development of tinnitus, and pre-treatment hearing
problems or new development of tinnitus should alert the treating clinician
to the need for formal assessment of the patient by audiometry. Hearing
loss at 8000Hz is predictive of early deterioration and suggests that further
cisplatin doses should be modified. Threshold evaluation in frequencies
below 6000Hz indicates serious ototoxicity and in most cases platinum
therapy should be discontinued in these cases.
Peripheral neuropathy is an additional and significant side-effect first
reported by Kedar and colleagues following a total cisplatin dose of
500mg/m2 [Kedar et al, 1978]. Damage is predominantly to the large
sensory fibres with numbness and tingling as the first symptom. Later,
proprioception is affected and a severe sensory ataxia can develop.
Symptoms may begin and progress after treatment with cisplatin has been
discontinued [Mollman, 1990]. The neuropathy appears to be dose
dependent, usually appearing after a cumulative dose of 300-600mg/m2.
Recovery may take a year or more, consistent with the histopathological
findings of segmental demyeiination [Marin and Rierson, 1979], The
severity of the neurotoxicity induced by higher doses of cisplatin is such that
it precludes their long term use [Bagley et al, 1 985],
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Another important toxic effect of cisplatin is that it alters gonadal function,
gonadotrophin levels and steroid hormone levels in humans. Sterility may
result from cisplatin treatment and this is a significant problem when one
considers the young age of many men treated for testicular cancer. The
testosterone depletion seen in adult male rats after cisplatin treatment is
most likely to be due to its effects on hepatic enzyme expression,
specifically on the hepatic p450 system [LeBlanc et al, 1992],
1.1d Prevention of cisplatin toxicity.
Attempts have been made to find compounds which may be given in
conjunction with cisplatin to reduce its toxicity. The introduction of
prehydration, diuretics and chloride loading to protect renal function has
been mentioned above. The concurrent administration of cisplatin given
intraperitoneal^ and sodium thiosulphate administered intravenously was
originally thought to reduce the nephrotoxicity of treatment [Howell et al,
1 983] but further investigation of the combination in animal models resulted
in the conclusion that the thiosulphate reduced the antitumour activity of the
cisplatin when they were given together [Aamdal et al, 1988]. The
modulating agent WR 2721 is a prodrug of the radioprotective thiol
compound WR1065. It has been shown to protect mice from the
nephrotoxic and myelotoxic action of cisplatin without compromising its
antitumour effect [Yuhas et al, 1 980]. It has been proposed from study of
the in vitro model system that cisplatin induced DNA damage can be
prevented by tissues first accumulating WR1065. In addition, WR1065 is
thought to increase enzymatic DNA repair through its effect on
conformational changes in DNA, so post cisplatin administration of WR2721
may also have a protective effect [Treskes et al, 1992].
Considering avoidance of neurotoxicity, a report by van der Hoop and
colleagues stated that an analogue of ACTH (Org 2766) was effective in
preventing neurotoxicity in 39 evaluable women with ovarian cancer who
were treated with cumulative doses of 494mg/m2 [van der Hoop et al,
1 990] . Further trials are required to confirm the results and to ensure that
the combination of drugs does not adversely affect cisplatin's antitumour
activity.
The introduction to the clinic of the 5-HT3 antagonist group of antiemetics
has significantly reduced the problem of cisplatin-induced nausea and
vomiting, as discussed above.
The fact remains that even if it were possible to minimise the many toxic
side-effects of cisplatin, the problem of resistance to the drug - either
primary or acquired - would continue to limit its therapeutic application. The
best way by which to circumvent these disadvantages may therefore be to
develop analogues of cisplatin which are at least equally effective in the
clinic but which induce fewer and less serious side-effects. This aim was
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partially achieved by the synthesis of carboplatin which is discussed below.
1.2 The development of carboplatin.
The need for the development of an analogue of cisplatin has been made
clear by the problems outlined above. It was in 1 978 that carboplatin (cis-
diammine-1,1 -cyclobutane dicarboxylate platinum II, CBDCA, JM8) was
synthesised (structure Figure 1.3) by Cleare and colleagues [Cleare, 1978].
Preclinical trials identified it as an agent which had efficacy similar to that
of cisplatin with a more acceptable toxicity profile [Harrap, 1985]. The
mechanism of action of carboplatin is believed to be the same as that of
cisplatin in that it too produces DNA inter- and intra-strand cross links. The
rates of reaction of the arms of carboplatin are significantly different, unlike
the case for cisplatin. Carboplatin induces formation of interstrand cross¬
links, and equal binding of the two compounds to cellular DNA in culture
was shown to produce equivalent cytotoxicity [Knox et al. 1986]. The
cyclobutane-dicarboxylato bidentate structure of carboplatin is more soluble
but less reactive than the chloride of cisplatin, making the carboplatin more
chemically stable than the parent analogue and this results in a larger dose
of carboplatin being required to achieve the same degree of cytotoxicity
[Knox et al, 1 986],





1.2a Clinical activity of carboplatin.
There have been criticisms that the individual role of carboplatin as an
antitumour agent has not been specifically determined [Von Hoff, 1 987], but
it has been established in several studies that it demonstrates at least
equivalent activity to cisplatin in the treatment of ovarian cancer [Advanced
Ovarian Cancer Trialists Group: 1 991 ]. One paper which described in detail
the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian
cancer was published by Adams [Adams et al, 1 989]. The clinical response
(CR + PR) to cisplatin was 19/40 patients compared with 27/40 for
carboplatin but there was no difference in two year survival between the
two patient groups. The toxicity of carboplatin was certainly less, with the
median number of vomiting episodes per cycle being eight times more for
cisplatin than for carboplatin. WHO Grade I renal toxicity was seen in
67.5% of the cisplatin treated patients compared with 2.5% of the
recipients of carboplatin (WHO, 1979). With the use of standard doses of
carboplatin, neither ototoxicity nor neuropathy was witnessed whereas 45%
of the cisplatin treated patients had evidence of hearing damage at
audiometry, and 22.5% of the cisplatin treated patients had WHO grade I
neurotoxicity. The reduction in renal toxicity following carboplatin as
opposed to cisplatin treatment allows repeated dosing and enables it to be
given to "salvage" patients who may have responded to cisplatin but in
whom deterioration in renal function has precluded further treatment.
Intraperitoneal carboplatin 300mg/m2 was delivered to patients with ovarian
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cancer who had macroscopic disease at second look laparotomy following
iv carboplatin. The response rate was lower than expected at 12% in the
25 evaluable patients [Guastalla et al. 1994].
The single agent usefulness of carboplatin in small cell lung cancer is
impressive with a 60% response rate in chemo-naive patients [Smith and
Evans, 1985]. This response rate can not be related accurately to results
obtained with cisplatin since the latter was not tested in a comparative
manner. Carboplatin and etoposide in combination as first-line therapy for
small cell lung cancer have been shown to achieve an objective response
rate of 85% in a study involving 52 patients, but as with other combinations
the initial response rates did not translate into improved response duration
(6 months in this study) or survival (9.5 months) [Smith et al, 1987].
Results for combination therapy with cisplatin and etoposide in the same
tumour were comparable at 86%, but nephrotoxicity occurred in 15/31
patients treated with cisplatin, a toxicity not seen in the carboplatin treated
patients [Evans et al, 1985]. Non small cell lung cancer has been treated
with carboplatin alone and in combination with cisplatin to exploit the
differential pharmacodynamic and dose limiting toxicities of the drugs. No
difference in efficacy was seen when the drugs were combined as first line
chemotherapy and delivered monthly to 76 patients. The overall response
rate was 13% in the 68 evaluable patients [Kreisman et al, 1990].
The frequent pre-existing renal damage in patients with bladder cancer make
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carboplatin an attractive alternative to the active cisplatin. However, the
effectiveness of carboplatin was less with only 3 partial responses (PR's) in
48 patients with stage IV disease [MRC Working Party in Urological Cancer,
1987].
In head and neck cancer, the single agent response rate with carboplatin
was ranged from 14 to 28% [Canetta et al, 1988] but combination with
other agents (eg.5-Fluorouraciland methotrexate) may enhancethe response
rate and results of trials are awaited.
In seminomatous tumours treatment with single agent carboplatin has been
shown to achieve very high response rates which translate into 2-year
survival rates of over 90%. In a study reported by Horwich and colleagues,
34 chemo-naive patients with advanced disease were treated with single
agent carboplatin 400mg/m2 at 4 weekly intervals. The 94% actuarial 2-
year survival rate was equivalent to that seen with aggressive combination
regimens and toxicity was significantly less (Horwich et al, 1989].
The documented activity of carboplatin in cervical cancer is equivalent to
that of cisplatin (response rate 12/46 or 26%) and toxicity in the Phase II
study was certainly reduced (Lira-Puerto et al, 1991). In advanced
endometrial cancer 28% of patients achieved a PR with median response
duration 129 days [Long et al, 1988].
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In advanced gastric cancer, the single agent activity of carboplatin in a
phase II study of 23 patients was 9% with dose schedule 1 30mg/m2 on
days 1,3 and 5 of a 28 day cycle [Preusser et al, 1 990]. The drug was well
tolerated with the only significant toxicity being haematological. The
duration of response was only 4 months and 11/20 patients subsequently
responded to second line chemotherapy.
A review by Smith and Talbot stated that single agent carboplatin in breast
cancer achieved a response rate of 28% in previously untreated patients
with advanced disease [Smith and Talbot, 1 992]. Predictably, the response
was significantly worse in previously treated patients, reaching only 3%.
There are only limited data on the use of carboplatin in combination
treatment for breast cancer, but the estimated response rate ranges from
25% to 44% in a pretreated patient population. High dose carboplatin
treatment in combination with thiotepa and cyclophosphamide resulted in a
response rate of 81% in a study involving 16 patients [Eder et al, 1990].
Prolonged responses have been reported in patients with ovarian cancer who
have undergone protracted treatment with carboplatin, raising the possibility
that response duration may be increased if the optimal duration of treatment
can be established [Muggia, 1 989]. One of the advantages of the reduced
toxicity of carboplatin compared with cisplatin is that more protracted
treatment is feasible and "rescue" is possible for patients with responding
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tumours who have unacceptable side-effects of cisplatin.
1.2b Toxicity of carboplatin.
Carboplatin is certainly less toxic than its predecessor cisplatin. Dose
limiting toxicity is myelosuppression fCalvert et al, 1982; Rose and Shurig,
1985]. There is a much smaller incidence of nephrotoxicity [Wiltshaw,
1985]. Sterility is not a problem encountered with carboplatin in contrast
to the previously mentioned effects of cisplatin [LeBlanc et al. 1992].
Pharmacokinetically, carboplatin is handled by the kidney in such a way that
its clearance approaches the GFR. This enables easier calculation of the
appropriate dose to be prescribed to avoid excessive myelotoxicity [Egorin
et al, 1984] and it can be used prospectively [Egorin et al, 1985]. The
original formula correlated platelet nadir (expressed as a percentage of the
pretreatment count) with the free platinum concentration/time data (area
under the curve or AUC in mg/ml x minutes) and required knowledge of the
pretreatment GFR, the body surface area and the patient's prior
chemotherapy status. Later, Calvert developed a formula which provides a
simple and consistent method of determining carboplatin dose in adults
where the measure of drug exposure is AUC and not toxicity: total dose
given (mg) = (GFR + 25)xAUC required. The advantage of this formula is
that it is not influenced by previous or concurrent myelosuppressive therapy
or supportive measures [Calvert et al, 1989], In addition, the formula allows
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calculation of the constant carboplatin exposure time when the drug is given
in combination and facilitates the estimation of actual dose given.
1.2c High dose carboplatin.
Several studies have been published where carboplatin has been
administered in doses higher than the conventional 400mg/m2 or AUC
6mg/ml x minutes. It was predicted that high dose carboplatin would result
in less severe toxicity than high doses of cisplatin and that
myelosuppression would be the main limitation to dose incrementation.
Carboplatin in doses of 800 to 1 600mg/m2 were delivered to patients with
lung cancer or mesothelioma without bone marrow rescue. A total of 16
patients were treated with 5 to 10 cycles of chemotherapy at 800, 1 200 or
1600mg/m2 with no intra-patient dose elevation [Gore et al, 1987].
Myelosuppression was the main toxicity and at the top dose the Grade IV
thrombocytopenia (from day 12) lasted from 8 to 33 days. Grade IV
neutropenia was of shorter duration (8 to 14 days). Ototoxicity was
documented in 3 patients at doses over 800mg/m2 and a mild peripheral
neuropathy was recorded in 3 patients, also at the higher dose levels.
In a study where carboplatin 300mg/m2 daily x5 was given to treat acute
leukaemia, ototoxicity was the dose limiting factor while continuous infusion
of 265mg/m2 x5 days resulted in myelosupression and alteration of liver
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function. It was postulated in the same study that the concomitant
administration of aminoglycoside antibiotics might have been the factor that
accounted for the difference in otoxicity witnessed [Lee et al. 1 987; Meyers
et al. 1 987],
More recently, haematopoietic growth factors were given concurrently with
infusions of autologous peripheral blood progenitor cells (PBPC) to reduce
the duration of myelosuppression from high dose carboplatin. There was a
significant reduction in the duration of neutropenia and thrombocytopenia
in the 18 treated patients when PBPC support was added to carboplatin and
granulocyte-macrophage colony stimulating factor (GM-CSF) therapy for the
second 20 (of a total of 40) courses of carboplatin at dose 1 200mg/m2 over
96 hours. The main aim of the trial was to ascertain and subsequently
alleviate the toxicity of the regimen, but a 70% response rate was seen in
the previously treated group of patients. The 3 complete responses (CR's)
were in patients with ovarian cancer. A 57% increase in the total dose of
drug was delivered to the patients who had haematopoietic growth factors
and PBPC [Shea et al, 1992]. These data are encouraging for those
oncologists who are currently investigating the role of dose intensity with
PBSC rescue in several solid tumour types.
Currently a study of high versus conventional dose carboplatin in initial
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treatment of advanced ovarian cancer is in progress at the Royal Marsden
Hospital. Using Calvert's formula incorporating the glomerular filtration rate
as measured by 51Cr-EDTA clearance to achieve a known AUC
representative of drug exposure time [Calvert et al. 1989], patients are
randomised to receive carboplatin doses to achieve either AUC6 or AUC
12mg/ml x minutes. Those patients randomised to the high dose arm
receive a total of four treatments at monthly intervals compared with six
monthly treatments delivered to those in the conventional dose arm of the
study. The results should test the contention of Jodrell and colleagues that
an increase of AUC from 5 to 7mg/ml x minutes will result in an increase in
toxicity without associated increase in response [Jodrell et ai, 1992],
1.3 Resistance to cisplatin and carboplatin.
Apart from the toxicity of cisplatin and carboplatin, the other problem that
severely limits their use in the clinic is the development of resistance. Even
in advanced ovarian cancer where the platinum-based drugs have produced
high complete response rates, prolongation of disease free survival and
statistically significant prolongation of overall survival, the majority of
patients will relapse. The likelihood of responding to a rechallenge with
platinum depends on the duration of response to the original treatment. In
a retrospective analysis of responses in patients with ovarian cancer who
were included in phase II studies, there was a significant increase in the
chance of a drug inducing an antitumour response if the patient had
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completed initial treatment more than six months previously and had
responded to it [Blackledge et al, 1 989]. The other factor which was shown
to be of relevance was the FIGO staging of the patient, with more advanced
disease predicting negatively for response. The importance of duration of
response to the initial chemotherapy treatment was supported by the
findings of Gore and colleagues who reported the response to a platinum
rechallenge as 57% if the original response lasts for more than two years
compared with 17% if progressive disease were detected less than 12
months from the first treatment [Gore et al, 1990].
Many different groups have investigated the mechanisms of resistance
development with the eventual aim of finding a means by which to reverse
or to overcome them. Attempts to predict the likelihood of a patient
surviving long term after an initial response to cisplatin have included study
of short-term in vitro chemosensitivity of tumour samples obtained at
surgery. One study involving 61 patients with stage III ovarian cancer
reported a positive predictive value of 72% and a negative value of 66% in
terms of a definite clinical outcome - survival or death - using an assay of
cisplatin-induced inhibition of cell proliferation [Khoo et al, 1988]. This
approach does not, however, consider the reasons for eventual relapse and
demise of the patient and is therefore of limited use in clinical practice.
There are several ways in which malignant cells may develop resistance to
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platinum chemotherapy. The mechanisms which have been investigated are
outlined below.
1.3a Studies of reduced accumulation.
Several authors have suggested that decreased accumulation of drug is a
mechanism of platinum resitance present in several different cell lines in
vitro [Eichholtz-Wirth and Hietel, 1986; Hromas et al, 1987a; Waud, 1987;
Richon et al, 1987; Kraker and Moore, 1988; Andrews et al, 1988a]. The
lack of evidence for increased efflux of drug suggests that the mechanism
of resistance to platinum in these cells may differ from that found in mouse
fibroblast NIH 3T3 cells which have been transformed with ras oncogenes.
The protein encoded by ras, was iocated on the inner surface of the cell
membrane and was associated with increased cisplatin resistance in these
cells. The postulate was that it may increase the cells' ability to pump out
cisplatin [Sklar, 1988].
An example where increased drug efflux contributes to resistance is that
found in neoplastic cells which are resistant to adriamycin, vinblastine,
actinomycin D and colchine. Multiple drug resistance (MDR) is known to be
associated with increased expression of the P170 P-glycoprotein (where P
represents permeability), which is encoded by the mdr1 gene and enhances
the cells' ability to pump out the drugs [Inaba et al, 1979; Kartner et al,
1 983]. To date, no evidence has been found to suggest that resistance to
the platinum drugs depends on a similar mechanism.
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On finding that the cisplatin resistant murine leukaemia cell line
(L1 210/cisplatin) bound 56% less platinum on its membrane than did the
sensitive L1210, Gross and Scanlon initiated a more detailed study of the
membrane of resistant cells. They concluded that resistance was associated
with a change in the transport of neutral amino acids. The L1 210/cisplatin
cells under study were found to have a much lower requirement for
exogenous methionine and a decreased methionine transport associated with
decreased threonine uptake [Gross and Scanlon, 1986], Shionoya and
colleagues confirmed that this was also the case in the platinum resistant
K562 chronic myeloid leukaemia cell line [Shionoya and Scanlon, 1986].
These results confirm that there is a change at the membrane level in
L1 210/cisplatin cells, but more detailed study of the lipid content, surface
membrane fluidity and temperature dependence of cisplatin accumulation in
sensitive and resistant human ovarian cancer cells showed that there was
no significant difference in the basic membrane structure between the two
cell lines [Mann et al, 1988]. Previous studies reported that cisplatin
accumulation is modulated by cAMP and depends on the membrane
potential [Andrews et al, 1 988a] but more recently, Andrews and colleagues
have concluded that the Na + ,K+-ATPase plays a central role in the cellular
uptake of cisplatin since inhibition of the Na + ,K + -ATPase by ouabain
dissipates the Na+ gradient and directly affects cisplatin influx [Andrews et
al, 1991].
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It was reported in 1981 that the coadministration of verapamil, a calcium
channel blocker, with the anticancer drugs vincristine and vinblastine led to
an increase in cytotoxicity fTsuruo et al, 1981] . A similar experiment was
then carried out to investigate the effect of administering cisplatin and
verapamil to Balb/c athymic mice bearing a transplanted human
neuroblastoma. The addition of verapamil was found to increase the
antitumour effect of cisplatin in this tumour [Ikeda et al, 1987], but it was
a different type of calcium channel blocker (nifedipine - dihydropyridine
class) that caused enhancement of antitumour activity in an inherently
cisplatin resistant Lewis lung carcinoma line fOnada et al, 1988]. There is
no evidence to date that calcium channel blockers increase uptake or
decrease efflux of cisplatin, but the fact remains that the important role of
the cell membrane in drug resistance is again emphasised by these findings.
1,3b The role of glutathione.
Glutathione is a tripeptide thiol found in virtually all cells at millimolar
concentrations, levels substantially higher than many other intracellular
molecules. Its role in cellular resistance was elucidated in the study of
resistant Ehrlich ascites tumour sublines reported by Revesz and colleagues
[Revesz et al, 1963]. All but one of the sublines which had resistance
induced by sublethal in vitro irradiation between passages contained an
increased concentration of non-protein sulfhydryl and were more resistant
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than the parent Ehrlich cell line to the growth inhibitory effect of 20Gy
radiation in nitrogen. In the presence of oxygen, all sublines were as
susceptible to the effects of radiation as the parent line. The theory
accepted as an explanation for the difference in sensitivity between these
cell lines was that GSH plays a role in detoxification of radiation-induced
toxins such as free radicals and/or the repair of critically damaged cell
structures. In addition to playing a role in cellular resistance to and repair
following exposure to radiation, Calcutt and Connors in 1963 reported that
the therapeutic response of some tumours to merophan, an isomer of
melphalan, correlated with the ratio of protein-free to protein-bound
sulfhydryl [Calcutt and Connors, 1963]. More recently Susukake and
colleagues showed that an L1210 leukaemia line made resistant to
melphalan contained a 2-fold greater concentration of GSH and could be
resensitised by lowering its GSH content [Susukake et al, 1982]. The
relationship between increased GSH and resistance both to radiation and to
several antineoplastic drugs was reviewed by Arrick and Nathan [Arrick and
Nathan, 1984]. It might have been expected that elevation in intracellular
GSH concentration would play a part in resistance to platinum-based
anticancer drugs because of the similarity in their action to that of the other
alkylating agents.
Further to the discovery of the effects of increased glutathione, it was
demonstrated that if the intracellular concentration were decreased through
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prolonged incubation of the cells with the specific (5-glutamylcysteine
synthetase inhibitor buthionine sulfoximine (BSO), the full sensitivity of the
cells to cisplatin was recovered [Hromas et al. 1987b; Andrews et al,
1 988b]. The mechanism by which GSH exerts its protective effect may be
either through reaction between cisplatin and GSH preventing active
electrophilic drug from reaching intracellular targets or, alternatively, GSH
may act as an important mediator in the repair of the damage to DNA
induced by platinum (Andrews PA et al, 1988b). Further research has
revealed that depletion of GSH with BSO does inhibit DNA repair, and that
treatment of the cells with glutathione ester after BSO exposure results in
complete recovery of DNA repair activity [Lai et al, 1989]. It has been
postulated by several researchers that the enzyme glutathione S-transferase
(GST) is more important than the tripeptide itself in platinum resistance. The
involvement of GST was first suspected when it was reported that
resistance in an adriamycin resistant human breast cancer subline was
associated with a 45-fold increase in GST activity [Batist et al, 1986].
However, no correlation between total GST activity and drug sensitivity was
measured in a detailed study of 14 parent and 15 drug- and X-ray selected
resistant sublines published by Hosking and colleagues [Hosking et al.
1990]. Modified GSTs have been identified in a range of multidrug
resistant tumour sublines but it is now thought that it is not the total GST
that is important, rather the differences in isoenzyme composition may




Metallothioneins are intracellular proteins rich in sulfhydryl groups
(composed of 30% cysteine) and they are believed to play a central role in
metabolism and storage of heavy metals in the body [Webb, 1972]. It has
been shown that cells which have a high concentration of metallothionein
are resistant to cisplatin [Bakka et al, 1981]. Although the initial
observations were made in cells which had been made resistant to cadmium,
elevated metallothionein levels have now been found in a cisplatin resistant
head and neck tumour [Teicher et al. 1987] and a prostate tumour line
[Metcalfe et al. 1986]. Cisplatin resistant ovarian cancer cells have also
been shown to contain an elevated concentration of metallothionein, but in
vitro selection with cisplatin did not increase the levels of these proteins
[Andrews et al, 1987a]. It may be that further investigation of the role of
metallothionein in drug resistance will offer a mechanism by which platinum
resistance may be overcome, but the first reports exploiting the results have
concentrated on the induction of metallothionein in the kidney using bismuth
subnitrate (BSN). Increased levels of metallothionein induced by this method
have been found to reduce the toxic effects of cisplatin without affecting its
antitumour activity [Satoh et al, 1 988]. More recently, studies on an L1 210
cell line and its cisplatin resistant variant (LI 210-PDD) have shown that both
lines contain metallothioneins which are inducible by exposure to zinc in
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vitro. Zinc induction of metallothioneins was less effective in the L1210-
PPD line which showed no cross resistance to zinc and a heightened
sensitivity to cadmium. L1 210 cells were found to produce metallothioneins
in response to cisplatin whereas the L1210-PPD did not. The pattern
suggested that enhanced synthesis of metallothioneins was not the
mechanism by which L1210-PPD cells were resistant to cisplatin
cytotoxicity [Farnworth et al, 1990].
1.3d Topoisomerase.
There is ample evidence to support the theory that platinum-DNA inter- and
intrastrand crosslinking interfere with replication of tumour cells (see section
1.1a above). It is possible that increased repair of the damaged areas may
confer resistance to platinum based drugs. DNA topoisomerases play a
major role in DNA repair, with topoisomerase II thought to be the more
important enzyme [Downes et al, 1988]. The adducts may become more
accessible to repair enzymes via alterations in the topology of DNA. The
interaction of cisplatin with drugs that affect topoisomerase was
investigated by Katz and colleagues using the human ovarian cancer cell line
2008 [Katz et al, 1990]. There was evidence of additive interaction
between cisplatin and topoisomerase I modulators camptothecin and B-
lapachone and between cisplatin and the topoisomerase II modulator
novobiocin. There was antagonism noted between cisplatin and the
topoisomerase II inhibitor etoposide despite the known clinical synergy of
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these two drugs.
The conclusion to be drawn from all of these experiments must be that there
is no single mechanism that imparts to malignant cells the property of
resistance to the platinum anticancer drugs. Innate and secondary
resistance is mediated through a combination of factors therefore the search
for agents which will reverse the resistance or for alternative platinum-based
chemotherapy will continue.
1.4 Studies of novel platinum-based drugs.
Despite advances in treatment of tumours with ever increasing doses of
cisplatin and carboplatin and continued investigation of the efficacy of
combination chemotherapy in the hope that a synchronous or even additive
effect in antitumour activrty may be discovered, one of the main thrusts of
research in cancer treatment is the search for novel platinum based drugs.
The aim is to discover one or more agents which have a broader spectrum
of activity coupled with less severe toxic side-effects. In addition to these
properties, ease of solubility and of formulation are essential features if a
drug is to become a viable antineoplastic treatment. The new platinum




The objective behind the development of tetraplatin (d,l-trans-isomeric 1,2-
diaminocyclohexane tetrachloroplatinum (IV); ormaplatin - structure Figure
1.4) was to produce a platinum complex which demonstrated activity
against cisplatin resistant tumour cells and demonstrated suitable
pharmaceutical properties for easy formulation. Tetraplatin was found to
fulfil these criteria, showing activity superior to cisplatin against the
P388/cisplatin, the intraperitoneal^ (ip) implanted murine L1210 leukaemia
and other tumours in vitro [Anderson et al, 1986], However, although
tetraplatin retained activity against the cisplatin-resistant L1210, it was
inactive against a correspondingly resistant murine ADJ/PC6 line [Goddard
et al, 1991]. In a phase I clinical trials of tetraplatin with administration of
drug on a day 1 and 8 schedule, the dose delivered ranged from 4.4 to
60.8mg/m2 [Schilder et al, 1994]. Although nausea and vomiting equal to
or greater than grade II was experienced by 40% of patients, it was said to
be well controlled with standard antiemetics. A delayed, severe
neurotoxicity was seen in 4 patients and was associated with cumulative
doses above 200mg/m2. One case of nephrotoxicity was also reported.
The fact that the trial was closed without selection of a suitable dose for
phase II studies suggests that the neurotoxicity witnessed in the phase I trial

















The cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV compound
(CHIP, JM9 - Figure 1.5) was developed in 1 978 and was found to be active
against the L1210 tumour and against plasmacytoma PC6 [Cleare et al,
1978]. Bramwell and colleagues reported on treatment of advanced ovarian
cancer in 28 patients treated with Iproplatin in a phase l-ll trial. Six
complete and 2 partial responses were achieved in 10 patients who had
received no prior chemotherapy, and 1 complete and 3 partial responses
were seen in 16 patients who had previously been treated with alkylating
agents [Bramwell et al, 1985]. Drug doses employed in the ovarian trial
were from 180mg/m2 to 350mg/m2 in three increments. Twenty-three
patients had undergone previous chemotherapy treatments. Responding
patients received a total of six courses of chemotherapy with Iproplatin.
There was no significant renal impairment, electrolyte imbalance, hearing
loss or peripheral neuropathy. The dose-limiting toxic effect was
thrombocytopenia which was dose related and cumulative. Neutropenia and
anaemia were also seen with 14 of the 39 patients in the trial requiring
transfusion. Gastrointestinal upset with explosive diarrhoea was a severe
and distressing side-effect of iproplatin treatment.
In squamous carcinoma of the head and neck, no antitumour effect was
seen in any of the 50 patients treated with Iproplatin 240-300mg/m2 every
four weeks for a total of 101 four week courses [Abele et al, 1987],
Iproplatin was shown to result in a response rate of only 8% (1/29) of
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patients with breast cancer when delivered at 45mg/m2 daily for 5 days
every month [Meisner et al, 1989]. All patients had received previous
chemotherapy.
1.4c DACCP.
DACCP (JM82 - structure Figure 1.6) is another of the diaminocyclohexane
analogues in which interest was initially shown because of its activity in
L1210 lines resistant to cisplatin [Burchenal et al, 1978]. The major
disadvantage of the drug was its restricted solubility. Phase I studies
revealed the dose-limiting toxicity to be thrombocytopenia. Renal toxicity
was seen at the higher dose levels of DACCP. Neurotoxicity was also
reported but nausea and vomiting were not unacceptably severe. Of the
tumours studied - testicular, ovarian, bladder, oesophagus, stomach, lung
and colon - no advantage was seen over cisplatin therapy, although some
of the patients had been extensively pretreated [Kelsen et al, 1982]. No
activity was found in a phase II trial of DACCP in refractory germ cell
tumours [Chun et al, 1985]. With formulation problems prominent and
without any evidence of a therapeutic advantage in using DACCP, the










The 1,1 -diaminomethylcyclohexane suifatoplatinum (TN06, Spiroplatin -
structure shown Figure 1.7) was initially thought to be less nephrotoxic than
cisplatin, but further studies revealed that severe, irreversible, occasionally
late onset and often fatal renal failure developed after treatment, and this
made its further investigation unacceptable [Offerman et al, 1 985; Colombo
et al, 1986; Van der Vijgh et al, 1988]. The extreme nausea and vomiting
it induced also mitigated against further clinical application of TN06 which
was, in any case, apparently devoid of significant clinical activity.
1.4e JM40.
No phase II studies of ethylenediamine platinum II malonate (JM40 -
structure Figure 1.8) have yet been published, but its reported toxicity in
phase I was less severe than that of TN06 or JM82. Nausea and vomiting
were again the main dose-limiting side effects. Although nephrotoxicity
occurred, it appeared to be reversible and myelosupression was not
documented. The neuropathy reported by several patients treated with
JM40 was not severe. Antitumour activity was present, with 2 PR's in the
phase I study but this and toxicity will be studied more carefuliy if JM40























A phase I report published on oxaliplatin (trans-1-diaminocyclohexane
oxalatoplatinum, 1-OHP; structure Figure 1.9) reported 4 partial responses
in 44 patients. Doses ranged from 45 - 200mg/m2 [Extra et al, 1990].
Although two of the responses were seen in oesophogeal cancer which is
usually resistant to single agent chemotherapy, the toxicity induced by the
drug was very concerning. The dose limiting toxicity was neuropathy which
was first seen at a dose of 135mg/m2 and continued thereafter, occurring
in 75% of the courses. Six patients developed Grade II! (WHO) neuropathy
after a cumulative dose of 500mg, and it was stated that a long-lasting
sensory neuropathy might result from treatment with the drug. The phase
II studies have shown encouraging activity in melanoma and gastric tumours
(overall response 5/16 and 5/8 respectively) and oxaliplatin will be studied
further [Christian, 1992].
1.4q Zeniplatin.
Phase I studies with 2,2-bis(aminomethyl)-1,3-propanediol-N,M'
1,1 cyclobutanedicarboxylato (2-)-0,0' platinum (Zeniplatin, Figure 1.10), a
third generation platinum compound, reported that the dose-limiting toxicity
was myelosuppression, especially leucopenia in heavily pretreated patients.
Nausea and vomiting were also significant, and grade 2 alopecia, mucositis
and diarrhoea were also seen. There was no ototoxicity or consistent
change in renal function [Dodion et al, 1 989]. Phase II studies with the drug
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in ovarian carcinoma reported an overall response rate of 16% in a
population of 23 evaluable patients. The median progression-free survival
in responding patients was 11 months with overall survival 81 % compared
with survival of 9 months in patients with progressive disease. Zeniplatin
had no direct effect on renal function as measured by isotope clearance, but
one patient who was treated on a "marginal" creatinine clearance suffered
from sudden and severe renal failure (Willemse et al, 1993). The Phase II
studies in non-small cell lung cancer showed a response rate of 33% in the
18 assessable patients, but again nephrotoxicity was a problem and will
seriously limit the further development of the drug [Jones and Smith, 1 991 ].
1.5 Screening for novel platinum drugs.
Much time, effort and money have been spent on attempts to improve on
cisplatin, and although carboplatin now has an important clinical role, the
search goes on to develop related antitumour drugs which are less toxic and
possibly more potent. In addition to improving the quality of response to
platinum drugs, the aim is also to identify agents which will demonstrate
antitumour activity against those cancers which have so far been resistant
to all forms of chemotherapy. Compounds which are to be tested for
oncological activity undergo very strict selection criteria prior to their
introduction to clinical trials, and the approach to screening varies in
different drug development centres.
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At the National Cancer Institute (NCI) in America, the Cancer Chemotherapy
National Service Centre (CCNSC) was established in 1955. The index
tumours used in screening coumounds were the L1210 and P388 murine
leukaemias, but a valid criticism of the drugs selected by this means was
that they were effective mainly against human leukaemia and lymphoma but
were of little use in treatment of more slowly growing soiid tumours.
Between 1975 and 1985, the sceening panel was changed in that animal
solid tumours and human xenografts were developed to provide a second
stage of drug selection, but the earlier problem of the type of drug found to
be active in the pre-screen remained.
From 1985, the NCI decided to introduce human tumour cell lines with an
in vitro assay as the primary cancer screen. The emphasis of drug screening
was therefore changed to a disease-orientated approach with cell lines
comprising a total of sixty different tumours - lung, colon, melanoma, renal,
ovarian, brain and leukaemia. The current arrangement is that each chemical
agent is tested in various concentrations against a wide variety of human
tumours of both solid and haematoiogical type. The system is now capable
of testing over 1 000 extracts every week, and since the full cancer screen
has been operational (April 1990) more than 27 000 defined chemical
entities and thousands of crude natural product extracts have passed
through the system. Only 4% of the screened compounds have been
selected for secondary in vitro and in vivo evaluation [Grever et al, 1 992].
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At the Institute of Cancer Research in Sutton (ICR), carboplatin was selected
for further investigation mainly on the basis of its activity against the
ADJ/PC6 murine plasmacytoma and the P246 human bronchogenic
carcinoma xenografted into immune-deprived mice [Harrap, 1985]. The
ADJ/PC6 provides the primary in vivo rodent screen for the identification of
active novel platinum containing compounds while the L1210 murine
leukaemia is used on an ad hoc basis. For both PC6 and L1210 tumours,
resistant variants of the parent cell line have been developed through
controlled exposure of the sensitive cells to cisplatin, carboplatin amd
tetraplatin.
In the case of L1210, the resistant lines are designated L1 210/cisplatin,
L1 210/carboplatin and L1 210/tetraplatin. Details of the development of
resistance are given later in the thesis. Another important feature of these
murine lines at the ICR is that they are all freely transferable between the in
vivo and the in vitro state thus enabling biochemical and pharmacological
studies to be carried out. This feature is useful in the investigation of
resistance development in tumours and provides an invaluable extension to
the drug screening panel.
A more recent addition to the bank of cell lines at the ICR are the human
ovarian cancer tumours. Six of these lines (named HX62, PXN94, OVCAR3,
41M, CH1 and SKOV3) have been introduced to the screening panel
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because of the differential sensitivity which they exhibit to several
'calibrating' platinum drugs - cisplatin, tetraplatin, carboplatin and iproplatin
(Figure 1.11). Details of the origins of these six cell lines - five of which
also grow as xenografts - are given in Chapter 5.4. Their importance in
drug development is that they may provide a more predicitve model of
tumour sensitivity in man.
Figure !• H Relative sensitivity of ovarian carcinoma cell lines
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1.6 Thesis aims.
Although the discovery and development of platinum containing anti-cancer
drugs has had a major impact on the successful treatment of many tumour
types, efficacy of the drugs is seriously limited by toxicity and by the
development of tumour resistance.
An initial means by which to investigate the problems (with a view to
overcoming them), has been to develop resistance to cisplatin, carboplatin
and tetraplatin in the L1210 murine leukaemia line in vitro. These variant
lines have been characterised biologically and have provided a model for the
study of biochemical mechanisms associated with resistance, for example
drug uptake, glutathione content and DNA platination. The methods
employed in resistance development and in investigating resistance
mechanisms are detailed in the thesis.
In addition, the resistant models have been used to screen both platinum II
and platinum IV novel compounds provided by the Johnson Matthey
Technology Centre. The novel compounds investigated have either shown
good clinical activity when administered systemically to animals bearing the
ADJ/PC6 plasmacytoma, or form part of a structure-activity series. Studies
with the resistant models form part of a programme to identify a third
generation platinum drug which may overcome the problem of resistance to
cisplatin and carboplatin.
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The other priority of the platinum programme is to identify a compound
suitable for oral administration in the clinic. A number of platinum IV
dicarboxylates have been found to demonstrate superior activity against the
ADJ/PC6 tumour in vivo when delivered orally rather than systemically.
These novel compounds have been evaluated for in vitro cytotoxicities
against the L1210 variant lines. Six "lead" compounds have also been
selected from the in vivo antitumour studies for further evaluation of their
cytotoxic effects against human ovarian cancer cells in culture. Detailed
pharmacology and haematological toxicity information has been obtained
using the six lead compounds in BALBc mice.
The final aim was to select one or two compounds for preclinical
development in the oral programme, and the first of these is currently being
evaluated in phase I clinical trials.
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CHAPTER 2
THE DEVELOPMENT AND CHARACTERISATION
OF A PLATINUM RESISTANT L1210 LINE.
2.1 Introduction.
In a paper published in 1956, Eagle and Foley reported on the cytotoxic
action of carcinolytic agents in tissue culture [Eagle and Foley, 1 956]. Since
then, many tumours have been grown in tissue culture and have played a
central role in the screening of novel compounds to assess their potential as
anticancer drugs. From the inception of tissue culture, the L1210 murine
leukaemia cell line has been the mainstay of drug screening systems, and in
more recent years the resistant variants of the L1210 line have become
important models against which new drugs can be tested.
The murine L1210 lymphoblastic leukaemia was first induced in mice aged
8 months after repeated skin painting with 0.2% 3-methylcholanthrene in
ethyl ether, as first described by Law (Law et al, 1 949). Since then, the cell
line has been continued by subcutaneous and intramuscular injection in
mice. The tumour has been used extensively in vitro and in vivo because it
adapts easily from growth as ascites.
Further analysis of the L1 210 line by Dowjat and Wlodarska suggested that
L1 21 0 may be a T-cell leukaemia because its karyotype revealed trisomy 1 5
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in 65% of the cells, a feature found in many other murine leukaemias known
to be of T-cell origin [Dowjat and Wlodarska, 1981], Monosomy of the X
chromosome was also reported and has previously been seen in transformed
lines, human and animal tumours [Sakurai et al. 1974], There were,
however, changes in the cytogenetic characteristics during the course of the
L1210 undergoing in vitro adaptation.
Like most experimental leukaemias, L1 210 is characterised by rapid growth -
namely a growth fraction close to 1. This property makes it of great value
in the determination of the phase specificity of new cytostatic agents as
well as providing a quick screen for effectiveness of novel compounds.
Conversely, those who criticise the use of the cell line in screening for
selection of novel anticancer drugs maintain that its rapid growth mitigates
against the discovery of agents which may be active against the more
slowly growing tumours, for example those of the gastrointestinal tract.
Although the trend is now away from the sole use of murine lines and
towards human tumour cell culture and xenograft evaluations which may
give a more accurate indication of the behaviour of human cancers, the
L1210 parent sensitive and resistant cell lines will retain an important
position in the screening programme since they provide an essential
historical reference to the background of selection of potentially clinically
active agents. For example, tetraplatin was chosen to enter clinical trials as
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a possible novel platinum anticancer drug on the strength of its activity
against an L1 210 cell line with acquired resistance to cisplatin [Anderson et
al 1986],
The in vitro growth of L1210 and other tumour models is valuable in that
resistant lines can be developed, tumour characteristics may be studied and
sensitivity to antineoplastic drugs may be established. Investigation into the
mechanisms of resistance can then be performed and the cell lines may also
be used to screen novel anticancer drugs.
In addition to detailing the method by which platinum resistance was
developed in the L1210 cell line in vitro, the characteristics of the resistant
cell lines have been ^established. One of the features of a cell which may
change with resistance development is the ploidy. It was therefore
important to establish whether the L1210 resistant lines had changed from
the diploid character of.the parent sensitive line using flow cytometry. Since
later studies were to require measurement of the cellular protein content, the
possibility that resistance development could be associated with a change
in cell volume and protein content had to be considered. These parameters
were compared in the parent L1210 line and the three variant lines resistant
to cisplatin, carboplatin, tetraplatin and iproplatin. The resistant lines are
referred to as L1 210/cisplatin, L1 210/carboplatin, L1 21 O/tetraplatin and
L1 210/iproplatin. The rate of cell growth, as measured by the doubling time
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of the cells, was also established for the resistant cell lines and compared
with that of the parent sensitive line.
The sensitivity profiles of the resistant L1210 cells were compared with
those of the parent cells using cisplatin, carboplatin, tetraplatin and
iproplatin. This allowed identification of patterns of cross-resistance in the
variant cell lines and speculation on the importance of structural differences
in compounds which can overcome resistance.
Finally, in order to assess the stability of the resistance induced in the
L1210 cells in vitro, the platinum resistant cells were cultured in drug-free
medium for a prolonged period of time with repeat measurement of their
degree of resistance at regular intervals.
2.2 Materials and Methods.
2.2a Development of resistance.
All cells were grown in suspension in RPMI 1640 medium supplemented
with 10% horse serum, 2mM glutamine and antibiotics (100U/ml penicillin
and 0.1mg/ml streptomycin).
Cisplatin, tetraplatin and iproplatin were formulated in 0.9% saline.
Carboplatin was dissolved in sterile water.
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To produce carboplatin resistance, parent sensitive L1210 cells were
exposed continuously to 2.5/vM carboplatin. This starting concentration was
selected because the IC50 of L1210 to carboplatin was 6//M and it was
noted that the sensitive cells had a 70% survival measured by
dose/response curve after exposure to 2.5//M carboplatin. Following growth
of the surviving fraction, the cells were re-exposed to the same
concentration to a total of 8 treatments at 2.5//M. The dose was then
escalated to 5/jM (9 treatments), 7.5/;M (17 treatments), 10//M (18
treatments), 20/yM (16 treatments), 30/vM (10 treatments) and finally 40/yM
(23 treatments) over a period of 1 6 months. At that time the cells were 1 3-
fold resistant to carboplatin when compared with the parent sensitive line,
as measured by continuous exposure to carboplatin for 48 hours.
Maintenance of resistance was ensured by twice weekly exposure to 10//M
carboplatin and the cell line doubling time was tested regularly.
The development of resistance to cisplatin, tetraplatin and iproplatin was
done in the same way, with sensitive cells undergoing constant exposure to
serially increasing concentrations of each drug. In each case retreatment
with fresh drug was instituted when the cells looked healthy and had
reached a concentration of at least 5 x 104/ml.
The stability of resistance in cells out of regular maintenance doses of




i) Preparation of standard.
Two female Balb C mice were sacrificed and their femurs removed. The
marrow content was washed out into 4ml PBS (Flow Labs) and brought to
a single cell suspension using a 19G needle and a 10ml syringe. The
suspension was then spun at 1 500rpm for 5 minutes. The supernatant was
discarded and the cells were carefully resuspended in 0.2ml ice-cold PBS.
A 10/vl sample was added to 10ml Isoton and the cell number counted on
the coulter counter, model ZM. The remainder of the marrow + PBS had
2ml cold 70% ethanol added and the sample was refrigerated.
ii) L1210 cell preparation.
A total of 5 x 106 cells per L1 210 cell line were required for cytofluorometric
analysis. Each cell line was grown in supplemented RPMI 1 640 medium as
detailed above to a concentration of 3-4 x 105/ml thus ensuring that cells
were in mid-log phase at the time of the experiment.
The resistant cells were prepared on the day of the analysis in a manner
identical to that outlined for the standards.
2.2c Cell sizing.
The volumes of the sensitive and resistant L1210 cells were measured by
coulter counter (model ZM) and pulse height analyser (Mevway) with the
help of Dr Trevor Macmillan.
72
2.2d Measurement of protein content.
The method of Lowry [Lowry, 1951] was used to measure the protein
content of the L1210 cell lines, all of which had been grown to a
concentration of 4 x 105/ml in the supplemented RPM! 1640 medium. In
this method, protein is precipitated with alkaline copper treatment and
measured using the Folin phenol reagent. A standard curve was prepared
using stock protein (Bovine serum albumin) 200/yg/ml in 0.1N NaOH.
Samples were read in a Beckman spectrophotometer at 750m//. Results
were expressed as //g protein/107 cells.
2.2e Measurement of IC50 in L1210 sensitive and platinum resistant cells.
All cell lines were grown to a concentration of 5x104/ml in medium as
detailed above. Cisplatin was prepared as described previously and added
to L1210/S at concentrations 2.5, 1.25, 0.625, 0.3125 and 0.156//M.
Cisplatin concentrations added to the L1 210/cis cells were 10, 5, 2.5, 1.25
and 0.625//M. In every case the volume of drug aded was 0.1ml to 5 ml
cells. Tetraplatin was added to L1210/s cells at concentrations 0.625,
0.3125, 0.156, 0.078 and 0.039//M. Tetraplatin concentrations added to





Table 2.1 demonstrates the time taken for the development of resistance to
the four platinum drugs. The time taken to develop the 10-fold resistant
L1 210/cisplatin line was 7 months compared with 1 6 months to develop 13-
fold L1 210/carboplatin resistance as described above. It took 12 months to
develop a 34-fold resistant L1210/tetraplatin line and the new
L1 210/iproplatin line had 7-fold resistance developed over a period of 18
months.
Table 2.2 summarises the characterisation of the resistant cells as compared
with the sensitive parent line. The doubling time of the L1 210/carbopiatin
cells is comparable to that of the parent sensitive line (15 hours v. 13.6
hours). There is no significant difference in protein content or in cell size.
All three resistant cell lines remain diploid.
TABLE 2.1
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In Vitro Development of Acquired Resistance











Tetraplatin 38 2 hours 4 months 34
Cisplatin 46 2 hours 6 months 10
Carboplatin 101 continuous 1 8 months 14
Iproplatin 51 2 hours 1 8 months 7
^Compared with IC50 value for the sensitive line. The IC50 value was
defined as the concentration of compound which reduced cell counts to
50% of control following continuous exposure for 48 hours.
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TABLE 2.2




























Figure 2.1 is a series of graphs of the flow cytometry of control, L1210
sensitive and resistant cell lines. The diploid character of the cells is
confirmed since all peak between 190 and 240.
Table 2.3 shows patterns of cross resistance to the 'calibrating 'platinum
drugs. There is partial cross-resistance to carboplatin (4.8-fold) in the 10-
fold L1210/cisplatin line. The 13.7-fold L1210/carboplatin line
demonstrates a 10.2-fold cross resistance to cisplatin, but there is no loss
of sensitivity to tetraplatin or to iproplatin. The 34-fold L1210/tetraplatin
cell line reveals remarkably little cross resistance to cisplatin and carboplatin
(3.1- and 3.5-fold respectively) and it remains completely sensitive to
iproplatin.
Table 2.4 documents the comparative IC50's of parent L1210 lines against
those of the resistant lines which have been grown free of maintenance drug
for two years. There is no significant difference in IC50 which confirms that
when resistance has developed it is stable even without exposure to the
platinum compound to which resistance was developed.
FIGURE 2.1
FLOW CYTOMETRY OF CONTROL MOUSE BONE MARROW SENSITIVE
AND RESISTANT L1210 CELLS
78
TABLE 2.3
Calibration of variant L1210 cell lines (cell count assay)
10501^)
L1210/S L1210/cis L1210/tetra L1210/carbo
Cisplatin 0.52 5.2 (10) 1.63 (3.1) 5.3 (10.2)
Carboplatin 6.2 29.5 (4.8) 22.0 (3.5) 85 (13.7)
Tetraplatin 0.12 0.14 (1.2) 4.1 (34.0) 0.14 (1.2)
Iproplatin 7.1 9.8 (1.4) 11.4 (1.6) 9.9 (1.4)
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TABLE 2.4
Comparative IC50 values for parent L1210 cells and resistant L1210 grown
maintenance-free for 2 years.
IC50 (//M) Resistance (-fold)
Cell line and drug
L1210/S v. cisplatin 0.65 -
L1210/cis v.cisplatin 4.2 6.5
L1210/S v.tetraplatin 0.16 -
L1210/tetra v.tetraplatin 4.3 2.7
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2.4 Discussion.
There was a marked difference in the relative ease with which resistance
was induced in the three cell lines in vitro (Table 2.1). L1210/tetra took
only four months and 38 exposures to the tetraplatin to achieve 34-fold
resistance compared with the L1210/S. L1210/carbo required continuous
exposure to carboplatin for 101 treatments over a period of 18 months
before a 14-fold resistance was developed. This finding might suggest that
the mechanism for resistance development is different in the L1 210 cell line,
depending on the structure of the drug to which resistance is induced. The
L1 210/iproplatin line took eighteen months to reach 7-fold resistance, and
the small number of exposures possible in the 18 month period is a
reflection of the toxicity of the drug to the cells which had protracted
recovery periods from 2 hour incubations in the drug.
There was no significant difference in protein content or in cell size between
the parent sensitive and the resistant L1210 cell lines in vitro (Table 2.2).
All three resistant cell lines remained diploid. These factors were important
because in later experiments where platinum uptake and DNA platination are
measured, results are expressed in terms of platinum content per mg of
protein. A change to tetraploidy would have doubled the amount of DNA
and rendered the conclusions invalid. The doubling times of the sensitive
and the resistant lines were also very similar (13.6 to 15 hours) and there
was no significant in the volume of the resistant L1210 cell lines (620 to
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750u3). The overall character of the resistant cell lines was therefore very
close to that of the parent sensitive line.
Cross-resistance studies were interesting in that there was partial cross
resistance to carboplatin (4.8-fold) in the 10-fold resistant L1 210/cisplatin
line. The 13.7-fold resistant L1210/carboplatin cell line demonstrated a
10.2-fold cross resistance to cisplatin, but there was no loss of sensitivity
to tetraplatin or to iproplatin. The lack of cross resistance could be related
to the difference in ease of develpoment to the drugs as discussed above.
The 34-fold resistant L1 210/tetraplatin cell line revealed remarkably little
cross resistance to cisplatin and carboplatin (3.1 - and 3.5-fold respectively).
All cell lines remained completely sensitive to iproplatin.
The development of resistance through exposure of the sensitive cells to
increasing concentrations of cisplatin, carboplatin and tetrapiatin is a
characteristic that remained stable in the cells even when they were cultured
in drug free medium for protracted periods of time - up to and beyond two
years. This suggested that the mechanism of resistance to the platinum
drugs - at least in the L1 210 murine leukaemia cells in vitro - was a feature
retained in the cell memory or genome to enable easy passage to the
progeny.
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It has not been established whether the resistant cells in vitro are
representative of the in vivo situation, but there are probably several
different and specific mechanisms involved to produce the patterns of cross
resistance (and lack of it) seen in the L1210 lines discussed above. Later
in the thesis, the results of screening of novel platinum based compounds
will be presented, and the variability of sensitivity profiles will again give
weight to the theory that different types of resistance are involved in the
various L1210 sublines.
The usefulness of the L1 210 resistant lines in screening of potentially active
anticancer agents is only one of their functions. The other important studies
facilitated by the development of such lines are those which investigate the
means of cells becoming resistant to established antitumour drugs. The
following chapter details in vitro work on the platinum drugs cisplatin,
carboplatin and tetraplatin where the mechanisms for platinum resistance in
L1210 cells is explored.
CHAPTER 3
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INVESTIGATION OF MECHANISMS OF PLATINUM RESISTANCE
IN L1210 CELL LINES
3.1 Introduction.
As discussed earlier, tumours are adept at developing resistance to
chemotherapy drugs and a better comprehension of the mechanisms of
resistance may allow circumvention of the problem. Platinum resistance
may come about through a genetic event which results in any or all of the
following:
a) Decreased drug accumulation (alteration in membrane transport)
b) increased drug extrusion from the cell
c) Activation of cellular thiol mechanisms
- glutathione and other low MW thiols
- metallothioneins
c) DNA related mechanisms
- decreased binding
- increased repair
- increased tolerance of DNA adducts.
In this chapter, alteration in platinum accumulation in the L1210 sensitive
and resistant cell lines is measured. In addition to measuring drug uptake,
84
efflux is assessed since it has previously been established that in some
cancer cells resistance to the natural product antineoplastic drugs is
mediated by an increase in the ability of the resistant cells to pump drugs
out of the intracellular domain, an effect mediated by the p1 70 glycoprotein
located in the cell membrane [Kartner et al, 1983].
Following studies on the accumulation of platinum, colony assay
experiments have been used to make an assessment of the ability of the
sensitive L1210 and resistant variants to withstand various intracellular
concentrations of cisplatin, carboplatin and tetraplatin. A similar experiment
comparing the cisplatin sensitivity of Hela (cervical cancer) and V79
(Chinese hamster ovary) cell lines demonstrated that when the survival of
the cells in colony assay was plotted against the intracellular platinum
concentration per gram of DNA, the more sensitive Hela cells had a lower
survival fraction for any given cisplatin concentration [Fraval and Roberts,
1979],
The relative importance in resistance of the other mechanisms outlined,
involving thiols and DNA platination, are addressed in chapter 4.
3.2 Materials and methods.
3.2a Growth of L1210 cell lines.
Parent sensitive L1 210 cells and their platinum resistant counterparts were
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subcultured in RPMI 1640 medium supplemented with 10% horse serum,
2mM glutamine (Flow Laboratories) and antibiotics (100 U/ml penicillin and
0.1 mg/ml streptomycin).
3.2b Measurement of intracellular platinum concentration.
i)"Uptake".
50ml aliquots of cells in duplicate at 4 x 105/ml (mid logarithmic phase of
growth) were exposed to varying concentrations of cisplatin or tetrapiatin
(up to 80//M) for 2 hours or to carboplatin for 24 hours. The longer duration
of drug exposure in the case of carboplatin was necessary because of its
chemical stability and slower rate of reaction. Cisplatin and tetrapiatin were
formulated in sterile 0.9% saline. Carboplatin was dissolved in sterile water.
Cell suspensions were then centrifuged at 800g for 5 minutes at 4°C,
washed once with phosphate buffered saline (PBS) and the resultant pellets
stored at -20°C prior to analysis. Thawed cell pellets were reconstituted in
water (8 x 107 cells/ml) and sonicated at 23kHz for one minute. 50//i of
sonicate was injected into a Perkin Elmer 306 flameless atomic absorption
spectrometer. The temperature was raised initially to 1400°C over 30
seconds and then to 2600°C.
An internal standard curve was constructed from varying concentrations of
chloroplatinum in 10% HCI (Aldrich) added to untreated cell sonicates.
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ii)"Efflux".
Cells were grown to a concentration of 4 x 105/ml prior to being exposed to
40/vM drug concentrations for 2 hours (cisplatin and tetraplatin) or 24 hours
(carboplatin). Cells were then washed in PBS and resuspended in fresh
drug-free medium. Intracellular platinum concentrations were measured
following a 2 hour period in drug free medium as described above.
3.2c Measurement of cellular protein content.
Protein content was estimated according to the colorimetric method of
Lowry [Lowry, 1951] as detailed in 2.2d. Final results are expressed as
nmoles of platinum per mg of protein.
3.2d Assessment of survival of sensitive and resistant L1210 cells in colony
assay.
In cell survival assays, 10ml of cells at 2 x 105/ml in duplicate were exposed
to varying concentrations (up to 80/vM) of cisplatin or tetraplatin for 2 hours
or carboplatin for 24 hours, followed by centrifugation at 800g, 4°C for 5
minutes. Cell pellets were washed once with phosphate buffered saline
(PBS), resuspended in 10ml of complete medium, serially diluted and 2ml
aliquots in duplicate added to polypropylene tubes (NUNC) containing 3ml
of medium supplemented with 20% horse serum and 0.1 2% w/v Agar Noble
(Difco Laboratories) at 45°C. Tubes were plunged into iced water to set the




Figure 3.1 shows the relative amounts of intracellular platinum measured
after exposure to 40//M cisplatin for 30, 60, 90, 120 or 240 minutes. To
ensure that platinum concentration would be easily measurable in
subsequent experiments, it was decided to use the 120 minute exposure
time for further uptake experiments involving cisplatin and tetraplatin. At
this time point the intracellular platinum concentration after 40//M cisplatin
was 200nmoles/mg protein. The cells were exposed to carboplatin for 24
hours because of its slower rate of reaction due to increased chemical
stability.
The graphs in Figure 3.2 demonstrate that for all three drugs cisplatin,
carboplatin and tetraplatin the L1 210 resistant variants contain less platinum
than do the parent sensitive (L1210/S) cells. The difference is most
significant at the 80//M dose of drug where the reduction in intracellular
platinum in the resistant cell lines is 43% (LI 210/cis), 33% (L1210/tetra)
and 35% (LI 210/carbo). The intracellular platinum content of resistant cell
lines was comparable after cisplatin and carboplatin at 0.4-0.5nmoles/mg
protein, but an increased amount (0.75nmoles/mg protein) was measurable
after 24 hours' exposure to carboplatin.
38
Figure 3.1 nmoles Pt/mg protein in
L1210/Cisplatin after exposure to 40pM Cisplatin
versus duration of exposure (minutes).
nmoles Pt/mg protein
Duration of Treatment (minutes)
Each point represents the mean of 3 experiments (+/- sd)
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Figure 3.2 Intracellular platinum levels in L1210 cells
(Error bars = S.E., duplicate cultures per point)
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The rate of loss of platinum from the cells is shown in Figure 3.3. There is
no evidence for an increased rate of efflux of platinum from any of the
resistant cells when it is compared with efflux from the parent L1210 line.
From these graphs the lower uptake of platinum in the resistant cell lines is
also evident: After cisplatin exposure the sensitive L1 21 0 have 0.45nmoles
of platinum per mg of protein compared with the cisplatin resistant L1210
which contain only 0.2nmolesPt/mg protein.
Figure 3.4 demonstrates the cytotoxicity of platinum drugs in L1210
variants in soft agar colony assays. Plating efficiency of control cultures
(400 cells plated) was 37%. Each resistant cell line shows markedly
enhanced survival following dosing with equivalent doses of drug. For
example, following exposure to 20//M tetraplatin for 2 hours, 0.001 % of the
L1210/S cells are alive compared with 65% of the L1 210/tetra cell line.
The graphs in Figure 3.5 compare cell survival (soft agar colony assay) and
initial intracellular platinum concentrations in the L1210 cells. Taking
carboplatin as an example, after 24 hours' exposure to 80//M of drug,
0.02% of L1 210/S survive with a platinum content of 0.6nmoles/mg protein
compared with 50% survival of the L1210/carbo cell line containing the
same intracellular platinum concentration. The enhanced ability to tolerate
any given concentration of intracellular platinum is seen in all three of the
platinum resistant L1210 cell lines.
Figure 3.3 Efflux of platinum from L1210 cells
(Error bars = S.E., duplicate cultures per point)
Cisplatin
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L1210/cis
nmoles Pt /mg protein
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Figure 3.4 Cytotoxicity of platinum to L1210 variants
in soft agar colony assays
































Figure 3.5 Correlation between cei! survival (soft agar colony assays)
and initial intracellular platinum levels in L1210 cells
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The results of these experiments involving sensitive and resistant variants
of the L1 210 cells confirm previous reports that one of the means by which
platinum resistance develops in these ceils is through a reduction in platinum
accumulation.
Before deliberating on the reasons for lower intracellular platinum
concentrations found after the resistant cells' exposure to the drug, it is
necessary to consider the mechanism by which platinum is taken up into the
sensitive cell population. Past investigation into transport mechanisms led
to the conclusion that mediated transport of drugs is a xenobiotic
phenomenon ie: mediation of entry of artificial substrates occurs by a
mechanism already functioning for the accumulation of naturally occurring
substrates. These existing mechanisms include passive diffusion across the
membrane, active transport (an energy dependent process) and mediated
transport which may involve the incoming substance being linked to a carrier
of some sort.
Gale and colleagues found that the rate limiting factor for platinum uptake
was the external platinum concentration and concluded that cellular entry
of cisplatin was by passive diffusion [Gale et al, 1 973]. However, Andrews
and co-workers argued that since the actual compound on which these
experiments were carried out was cis-dichloro(dipyridine)platinum II, it was
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possible that the pyridine ligands may have had a significant effect on
cellular uptake of the compound, making it poorly predictive for what
happens with cisplatin [Andrews et al, 1 988]. In the same paper, Andrews
stated that the intracellular concentration of cisplatin did not equate with an
extracellular concentration of 1 //M until 4 hours for the parent sensitive cells
and 16 hours for cisplatin resistant cells, thus providing evidence against
cisplatin being transported uphill against a concentration gradient by active
transport. Likewise, the finding that the intracellular cisplatin aquated and
rapidly platinated other cell elements leaving only 10% intact platinum in the
cell mitigated against the suggestion that active transport is involved in the
process of platinum entering cells, despite the fact that the intracellular
platinum concentration eventually surpassed the extracellular concentration -
a situation normally indicative of active transport. Conversely, the discovery
that Dinitrophenol (an oxidative phosphorylation inhibitor), sodium fluoride
and iodoacetate (inhibitors of glycolysis) did decrease accumulation when
used in combination led Andrews and his colleagues to conclude that 50%
of cisplatin transport was in some way energy dependent.
The evidence against a carrier being involved was the finding that cisplatin
uptake was not saturable up to a concentration of 100/yM, and that
structural analogues of cisplatin did not appear to inhibit competitively
cisplatin accumulation [Andrews, 1988].
96
It has previously been proven that the toxic effect of the highly water
soluble cisplatin can be reduced by adding amino acids to the medium
[Byfield and Calabro-Jones, 1 981 a]. Considering this finding together with
the documented methionine requirement of sensitive cells, the postulate that
cisplatin is taken up into the cell at least partially by an amino acid transport
mechanism would appear to be acceptable.
If a carrier dependent transport system for platinum does exist, it follows
that resistance to this group of compounds could stem from somatic
mutations that yield cells whose membrane carriers are fewer in number or
possibly have a decreased drug affinity. In contrast, indications for the
involvement of a carrier system in cellular platinum uptake was provided by
Gross and Scanlon who demonstrated altered membrane transport properties
in L1210 sensitive compared with cisplatin resistant cells [Gross and
Scanlon, 1986]. The sensitive line exhibited a greater dependence on
exogenous methionine for optimal cell growth than did the line resistant to
cisplatin. There was a 2- to 5-fold decrease in initial uptake of methionine,
methylaminoisobutyric acid and threonine in the resistant cells. Altered
substrate specificity for methionine and threonine in L1210/cisplatin was
demonstrated by amino acid competition experiments. These findings for
L1210 also held true for the situation in K562, a chronic myelogenous
leukaemia cell line, and for L562/cisplatin cells where changes in plasma
membrane essential amino acid transport systems were concomitant both
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to the development of resistance and to the restoration of sensitivity to
cisplatin.
Cisplatin is known to bind to cell membranes and may cause membrane
lesions. Gale and colleagues stated that heavy metals and compounds
which compromise membrane permeability enhance the amount of platinum
bound per cell [Gale et al. 1 973]. An increased ability of the cell to prevent
or repair membrane lesions may be one method of developing resistance.
This can not be the whole story, however, since Hromas demonstrated that
reduced accumulation is not simply a membrane-mediated phenomenon by
preincubating resistant cells with drugs which increase membrane
permeability to prove that their sensitivity to anticancer drugs was not
restored [Hromas et al, 1 987], In a similar study, Mann compared the lipid
content, surface membrane fluidity and effect of temperature on cisplatin
accumulation in sensitive and resistant human ovarian cancer cells, and
discovered no obvious difference in the characteristics between the two cell
lines [Mann et al, 1988]. In earlier experiments, Richon had demonstrated
that increasing the degree of resistance in cells did not produce a
corresponding decrease in their accumulation of drug (Richon et al, 1 987).
These findings mitigate against a straightforward membrane change being
responsible for resistance development.
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A decrease in the ratio of sodium potassium adenosine triphosphate
(Na + ,K+- ATP) molecules to protein was found in a human ovarian
carcinoma cisplatin-resistant cell line (2008/DDP) which accumulated less
cislatin due partially to alteration in the potential of plasma and
mitochondrial membranes [Andrews et al. 1991]. It was concluded that
cisplatin uptake was partially Na+ dependent and that maintenance of the
Na+ pump by Na + ,K+-ATPase would play an important role in determining
how much cisplatin entered the cell.
Experiments detailed in this chapter do not suggest an increase in platinum
efflux as a mechanism for cellular platinum resistance in the L1 210 cell line,
making it very unlikely that the multidrug resistance gene (mdrl) is relevant
in these cells.
The second set of experiments described in this chapter demonstrate the
increased survival in colony assay of resistant L1210 cells over sensitive
cells for any given concentration of intracellular platinum. This finding
supports the theory that there are factors other than reduced accumulation
involved in the resistance of tumour cells to the platinum anticancer drugs.
Although the mechanism behind improved survival of platinated DNA in
resistant cells is obscure, the possible explanations include:
1) resistant cells have less platinum attached to their DNA,
2) the DNA sites platinated in resistant cells are different from, and less
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important than, those platinated in sensitive cells, or
3) the resistant cells are better able to recognise and repair the DNA damage
induced by the platinum.
Experiments which help to determine the answers to these questions are
described in the next chapter.
CHAPTER 4
100
INVESTIGATION OF THE ROLE OF GLUTATHIONE
AND DNA PLATINATION IN RESISTANCE
4.1 Introduction.
Glutathione (GSH) is a tripeptide which is the major intracellular non protein
sulfhydryl compound, its functions are protean and include detoxification
of xenobiotics, amino acid transport, synthesis of DNA precursors and
protection from free radical damage. As early as 1963 it was stated that
the ratio of protein-free to protein-bound sulfhydryl compounds correlates
with the therapeutic response of selected tumours [Calcutt and Connors,
1963]. Measurement of the levels of glutathione in sensitive and resistant
cell lines confirms that in some cells an elevated concentration of GSH is
associated with increased resistance to anticancer drugs [Arrick and Nathan,
1984; Russo et al, 1986].
It has previously been reported that in several cell lines the sensitivity to
anticancer drugs can be increased by chemically mediated reduction of the
intracellular glutathione using the specific r-glutamylcysteine synthetase
inhibitor buthionine sulfoximine (BSO) [Hamilton et al, 1985; Hromas et al,
1987], In other studies there was no effect on cisplatin cytotoxicity
following BSO-induced GSH reduction [Richon et al, 1987; Teicher et al,
1987].
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To date there has been no firm conclusion regarding the mechanism of the
increased resistance to platinum drugs associated with GSH elevation, but
several theories have been submitted:
a) Alteration of platinum membrane transport.
b) Drug inactivation by the formation of an inactive GSH-platinum complex
in the cytosol.
c) Decreased binding of the platinum to DNA.
d) Increased repair of the DNA lesions [Behrens et al. 1987]. The
mechanisms are discussed in detail later (section 4.4).
In this chapter, the results are presented of GSH levels measured in the
parent sensitive L1210 compared with the levels in the resistant lines
L1 210/cisplatin, L1210/tetraplatin and L1210/carboplatin. The possibility
has been explored that the GSH concentration in the cells may change after
platinum exposure. The effect on sensitivity of decreasing the intracellular
GSH has been investigated by exposing the resistant ceils to BSO and
subsequently measuring their IC50 against cisplatin, carboplatin or
tetraplatin.
Finally, to assess whether decreased binding of platinum to DNA does play
a role in platinum resistance in the L1210 cell line in vitro, the platinated
DNA has been extracted and measured by atomic absorption
spectrophotometry.
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4.2 Materials and Methods.
4.2a Measurement of GSH.
All L1210 cell lines were grown in supplemented RPMI 1640 medium as
detailed in section 2.2a.
Cells were diluted to 2.5x104/ml with fresh medium on the day prior to each
experimentto normalise for extracellular cysteine content [Post et al. 1 983].
GSH levels were measured in the following experiments:
i) in untreated sensitive and resistant cell lines over a 48 hour culture period,
ii) in sensitive and resistant cells which had been exposed to 40//M cisplatin
or tetraplatin for 2 hours, or to 40//M carboplatin for 24 hours (the
concentration used for platinum accumulation studies), and
iii) in sensitive and resistant cells exposed to the relevant IC50
concentrations (cell count assay, 48 hours' continuous exposure) for each
compound.
At each time point 107 cells, in duplicate, were harvested by centrifugation
and washed twice with phosphate buffered saline (PBS). Cell pellets were
stored at -40°C prior to analysis and then lysed in 1ml of distilled water and
deproteinised by addition of sulphosalicylic acid (to 3% final concentration).
Samples were centrifuged at 10,000g for one minute in a Beckman
microfuge and the supernatant assayed for total glutathione as described by
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Suzukake [Suzukake, 1982] using the enzyme recycling method of Griffith
[Griffith, 1980].
The incubation mixture for determination of total GSH consisted of 100//I of
1 M triethanolamine HCI buffer (pH 8.0), 700//I of 0.3mM NADPH, 100//I of
6mM DTNB and 0.48 units of glutathione reductase. All reagents were
prepared in 125mM sodium phosphate buffer containing 6..3mM sodium
EDTA (pH 7.5). The absorbance of 2-nitro-5-thiobenzoic acid at 412 nm
was monitored spectrophotometrically.
Results were expressed as //moles of glutathione per mg of protein.
Reduced glutathione was then derivitised with 2-vinylpyridine but no
oxidised glutathione could be detected in the above samples.
In glutathione depletion studies, buthionine sulphoximine was added to cell
cultures (2x104/ml) to a final concentration of 25//M (a concentration which
was non-cytotoxic to cells over a 72 hour incubation period) 24 hours prior
to addition of platinum compounds. IC50 concentrations after a further 48
hours and glutathione levels at 4, 24 and 48 hours were assessed as
described above.
4.2b DNA extraction experiments.
One litre of each cell line at 2 x 105 cells/ml (2 x 108 cells total) were
required for each drug concentration. The cells were exposed to cisplatin
at 10, 20. 40 and 80//M for 2 hours. They were then centrifuged for 10
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minutes at 3500g, 4°C in a Beckman J6-B centrifuge with zero braking. The
supernatant was discarded and the cells were washed once in ice-cold PBS
by resuspension and centrifugation. The cells were then centrifuged as
above, the supernatant decanted and the pellets were flash-frozen and
stored at -20°C until further analysis.
The pellets were thawed into lysing solution (6% w/v paraaminosalicylic
acid, 1 % w/v sodium chloride, 1 % w/v triisopropylnaphthalene sulphonate
and 6% v/v secondary butanol in aqueous solution) at a concentration of
1ml lysing solution per 2 x 107 cells. An equal volume of phenol reagent
(500g phenol, 0.5g 8-hydroxyquinoline, 75ml of m-cresol and 55ml of
water) was added and the tubes mixed by inversion to partition out the
protein. The solution was transferred to polypropylene tubes and
centrifuged at 4000rpm, 10°C for 10 minutes. The upper aqueous layer
was removed into 50ml glass conical flasks with stoppers. Double the
existing volume of ethoxyethanol was added (to precipitate the DNA) and
the flasks were then gently agitated on a shaker for 5 minutes. The DNA
was removed with a spatula and 30ml ethanol was added to rinse away the
solvents. The DNA was washed a further twice with ethanol and the
ethanol was then drained off. The DNA was redissolved in 4ml deionised
water over a period of 1 hour. Sodium acetate 10% was then added to
bring the final sodium acetate concentration to 1 % in order that the DNA be
brought down as a sodium salt. 100//I of 1 % RNAase was then added and
the tubes placed in a water bath for 10 minutes. 100/vl proteinase K was
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then added and the solution incubated for a further 30 minutes at 37°C.
After transferring the contents to a polypropylene tube, an equal volume of
phenol reagent was added and the tubes were shaken well. Tubes were
then centrifuged at 4000rpm at 10°C for 5 minutes. The upper layer was
removed into universal containers and ethanol was again added to
reprecipitate the DNA. The DNA was washed twice more with ethanol and
finally with ether and transferred to preweighed, labelled microfuge tubes.
The ether was drained off and the tubes were left in a 37°C incubator to
dry. The tubes were finally placed in a dessicator under vacuum for a 48
hour period to remove any water still associated with the DNA.
4.2c Measurement of DNA platination.
Cells at a density of 4 x 105/ml (5 x 107 cells per point) were exposed to
various concentrations of cisplatin (up to 80//M) for 2 hours. Cell pellets
were washed with PBS and incubated overnight at 37°C in lysing solution
(10mM TRIS, 10mM edta, 0.15M NaCI, 0.4% SDS) containing 1mg/ml
proteinase K. Residual protein was removed by extraction with phenol
reagent (500g phenol, 75ml cresol, 55ml water and 0.5g hydroxyquinolone).
Following centrifugation, DNA was precipitated from the aqueous phase
with ethanol, washed twice with 80% ethanol, dried and dissolved in TE
buffer. After incubation with 1 % ribonuclease to remove contaminating
RNA, the solutions were re-extracted with phenol reagent, DNA was
reprecipitated as described above and digested in 0.2% nitric acid prior to
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analysis. Platinum associated with DNA was measured by flameless atomic
absorption spectroscopy on a Perkin-Elmer 1100b AAS.
Calibration of the AAS was achieved through injection of 50//I samples of
12.5, 25, 50, 75 and 100ng chloroplatinum prior to and subsequent to
measurement of the experimental samples.
UV absorbance of diluted DNA hydrosylate (5/vl + 4ml water) was used to
measure the amount of DNA present. Results were calculated from the
knowledge that 1mg/ml DNA gives an optical density of 26 at wavelength
266.
4.3 Results.
Table 4.1 lists the glutathione levels as measured in L1210 sensitive cells
compared with L1 210/cisplatin, L1 210/carboplatin and L1 210/tetraplatin
from time zero prior to exposure to any drug to 48 hours after passage. It
can be seen that there is little difference in the GSH concentrations between
sensitive and resistant cells. In agreement with Batist and colleagues [Batist
et al, 1986b], cellular GSH levels were dependent upon time after subculture
in fresh medium and were lower at 48 hours compared with earlier time
points. While the GSH content of the L1 210/cisplatin and L1 210/tetraplatin
were comparable with that of the L1210/sensitive line, the GSH content of
the L1 21 0/carboplatin was approximately twice that of the parent sensitive
line during the first 24 hours of culture.
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TABLE 4.1




Total Glutathione Content (mmols/mg protein)
L1210/S L1210/'cis L1210/tetra L1210/carbo
0
t
78 ± 20* 91 60 147
4 58 ± 12 76 83 119
24
\
64 ± 14 61 55 130
48 45 ± 18 49 47 66
* Each value represents the mean of determintions from duplicate cultures unless otherwise
■ndicated.
5 Starting cell densities range from 3.1 to 6.8 x104 cells/ml
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Table 4.2 demonstrates the GSH levels measured at 4, 24 and 48 hours in
resistant cells exposed continuously to the IC50 or exposed for 2 hours to
40/yM concentrations of cisplatin or carboplatin. With carboplatin, the cells
were exposed to the IC50 (6.2//M) or 85/yM continuously or to 40/yM for 24
hours. Neither tetraplatin nor carboplatin exposure resulted in alteration of
the cellular GSH content of sensitive and resistant L1210 cell lines. There
was a 36% increase in GSH content of the L1210/cisplatin 24 hours
following exposure to 40//M cisplatin for 2 hours but the change was not
sustained at 48 hours.
Table 4.3 shows that 24 hours after treatment with BSO 25//M there is a
reduction of the GSH content by >75% in all the resistant cell lines. The
GSH remained depleted by >50% after 72 hours' continuous exposure.
The final column shows the ratio of the IC50 values in the three resistant
cell lines expressed as a percentage of the IC50 without BSO exposure. The
L1210/carboplatin cell line demonstrated a fall in IC50 indicative of
increased sensitivity to platinum (ratio of IC50's 79%) but there was no
return of sensitivity to L1210/cis and L1210/tetra.
TABLE42
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Figure 4.1 demonstrates the decrease in the amount of platinum bound to
the DNA of the resistant cells (LI 21 O/cisplatin or R on graph) following
exposure of the cells to 10, 25, 50 or 100//M cisplatin for 2 hours. The
difference is most marked at the 80//M cisplatin concentration where
average DNA platination is approximately 50% less in the resistant cell line
(R) than in the parent sensitive L1210 (S).
4.4 Discussion.
These experiments demonstrate that at the time points examined, there is
no significant elevation in glutathione in our platinum resistant L1210 cell
lines. Other groups have also demonstrated that GSH appears to be
unrelated to L1 210 platinum resistance [Andrews et al, 1 987; Richon et al,
1987; Waud, 1987].
Depletion of the intracellular GSH by incubation of the resistant L1210 cells
with BSO had remarkably little effect on their sensitivity to the platinum
compounds. Following BSO exposure, cellular GSH concentrations were
reduced to 24% of the untreated concentrations and alteration in sensitivity
should have been seen if GSH were an important factor in platinum
resistance in these cells.
In many human ovarian cell lines grown in vitro, GSH concentration is
elevated in drug resistant variants. In the 2780 ovarian cancer cell line,
Figure 4.1 Pt/DNA Binding in L1210 Cell Lines
after 2 hours (error bars = s.d.)
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which was cloned from an untreated patient, the GSH level in the cisplatin
variant line was three times higher than that found in the parent sensitive
strain [Louie et al, 1985]. The OVCAR3 and 0VCAR4 ovarian cancer cell
lines were grown from patients who had already developed resistance to
radiation, to cisplatin and to other antineoplastic drugs. They also had very
high GSH concentrations. In contrast, the C0L0316 and 2008 human
ovarian cancer cell lines (in which Andrews and colleagues developed
cisplatin resistance) showed no elevation of their GSH levels as resistance
appeared [Andrews et al, 1985].
At the Institute of Cancer Research, a relationship between intracellular GSH
levels and platinum cytotoxicity has been established for eight human
ovarian carcinoma cell lines which demonstrate varying sensitivities to the
four platinum drugs cisplatin, carboplatin, tetraplatin and iproplatin [Mistry
et al, 1991]. The intracellular GSH concentration was related to the cells'
resistance to cisplatin, carboplatin and iproplatin, but not to the tetraplatin
resistance. Following depletion of GSH with BSO, there was a differential
effect on the sensitivity to the platinum II compounds (cisplatin and
carboplatin) compared with the platinum IV compounds (tetraplatin and
iproplatin) in that the cytotoxicity of the latter drugs was substantially
enhanced in all cell lines. There was enhanced cytotoxicity of cisplatin and
carboplatin only in one relatively sensitive and in one of the two relatively
resistant cell lines.
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In BSO depletion experiments with cisplatin resistant 2008 ovarian cells, it
was found that prolonged incubation with BSO was necessary to obtain a
reduction in GSH significant enough to enhance cisplatin cytotoxicity
[Andrews et al, 1988], Poor recovery and increased cisplatin cytotoxicity
were also to be found in resistant cells maintained in stationary phase for 4 -
96 hours prior to placing cells in conditions that permitted cell division. The
oxidative stress of passaging A2780 cells can induce an increase in the GSH
peroxidase and reductase which peaks on day 2 in the resistant cells,
compared with a peak on day 4 seen in sensitive cells [Batist et al, 1986].
Hamilton and colleagues found no evidence of increase in any of the GSH
related enzymes in the A2780 cell line, but the enzymes were measured at
only one time point in untreated cells [Hamilton et al, 1985].
One of the other postulates at the start of this chapter was that elevation
of intracellular GSH may result in a decrease of the platinum binding to the
DNA. Work by Andrews and colleagues has shown that GSH detoxifies
intracellular platinum and protects DNA from platinum-induced damage
[Andrews PA 1986], To recapitulate on the evidence behind the central role
of DNA in platinum toxicity, Roberts showed in 1981 in the ADJ/PC6
tumour in vitro that, taking account of the molecular weights, DNA. was
more extensively platinated on a molecular basis than either RNA or protein
[Roberts, 1983]. The crosslinking of DNA - as described in section 1.1 -
inactivates it as a template for further replication.
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In the experiments investigating DNA platination described above, it was
demonstrated that there was reduced platination of the DNA in the resistant
L1210 cells (Figure 4.1). Since it has already been shown that there is no
elevation of GSH in these resistant cells, it is not possible to challenge the
statement that in the L1210 cell line in vitro, GSH does not protect a critical
DNA target [Andrews et al, 1986], but the findings do contrast with the
results of Foka who stated that cisplatin resistant and sensitive L1 210 have
a similar amount of a cisplatin dose (about 20%) bound to the DNA [Foka
et al, 1988].
Others have also shown a relationship between DNA platinum adducts and
tumour sensitivity. Reed and co-workers found that in patients with ovarian
cancer, sensitivity to single agent cisplatin or carboplatin was associated
with an increased number of DNA platinum adducts on their leucocytes than
were found in the patients who had resistant disease [Reed et al, 1 987], In
that study, a cisplatin-DNA ELISA was used to measure adduct formation.
The correlation between better tumour response to platinum and an
increased number of cisplatin-DNA cross-links in leucocytes was also
reported Fichtinger-Schepman and colleagues [Fichtinger-Schepman et al,
1987].
In addition to measuring the number of platinum-DNA adducts, it is also
necessary to consider the importance of the ability of the cells to repair the
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damage to their DNA because a difference may exist in the capacity for
repair between sensitive and resistant cells. The rate of repair of platinated
DNA has not been studied in our L1210 cells, but a discussion of the
available information follows.
It has been suggested that resistant iines are better able to survive platinum
adducts on their DNA because they exhibit more efficient recognition and
repair of the bidentate interstrand X-link between adjacent N7 guanines
[Strandberg et al, 1982; Behrens et al, 1987; Masuda et al, 1988]. Some
cells which are less effective in removing interstrand cross links manifest
increased sensitivity to cisplatin - for example, repair-deficient Chinese
hamster ovary cells [Meyn et_a], 1982] and cells derived from people who
suffer from Fanconi's anaemia [Ploov et al, 1985]. Investigation of a human
ovarian cancer cell line (A2780) which was 5-fold resistant to cisplatin
showed that it demonstrated a 2-fold increase in the ability to repair
cisplatin induced damage compared with the parent sensitive line. It has
also been noted that after treatment with the specific DNA polymerase-a
inhibitor Aphidocolin, there was dose-dependent inhibition of recovery of
damage post cisplatin in the resistant cells and an increase of cisplatin
toxicity in these cells [Masuda et al, 1988; Lai et al, 1988].
Alternatively, it might be supposed that a cell line which demonstrated an
enhanced ability to repair DNA cross-links induced by platinum would be
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able to replicate almost normally. In an elegant series of experiments where
a resistant human bladder cancer cell line (RT11 2) and a platinum sensitive
germ cell tumour cell line (SUSA) were compared for rate of repair of cross¬
links, it was demonstrated that SUSA cells were unable to repair DNA-DNA
interstrand cross-links, whereas 50%-85% of these lesions were removed
in RT112, 24 hours after exposure to cisplatin [Bedford et al. 1988].
Moreover, the interstrand cross-links continued to form over the entire 24
hour period of observation in the SUSA, while the repair component became
dominant over interstrand cross-link formation in the RT112 at 14 hours.
A further explanation of resistance, suggested at the beginning of the
chapter, was that a population of resistant cells may be less sensitive to the
DNA cross-links induced by platinum. Hansson and colleagues found that
some human melanoma cells have a higher capacity to maintain DNA
synthesis in the presence of DNA cross-links [Hansson et al, 1988]. It has
not been established whether this is because of a lower sensitivity of the
DNA replicating enzymes of these cells to the presence of DNA interstrand
cross-links.
To return to the L1210 cell lines used to generate results discussed in this
chapter, it has been shown that in cisplatin resistant L1210 there was an
increased capacity for repair of DNA but the extent of repair did not
correlate directly with the degree of resistance of the cells [Eastman and
Schulte, 1 988].
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Further investigation into the mechanisms of platinum resistance in L1210
cells is under way. From the experiments described above, it is clear that
there is little evidence to support any single theory as an explanation for
resistance.
Moreover, whatever light is eventually shed on the mechanisms of
development of platinum resistance in cancer cells - and even if some means
to reverse resistance is identified - it will remain important to discover and
develop new drugs which will be active against resistant tumours. The
background to the search for novel antitumour drugs and an appraisal of
some new compounds will be presented in the following chapters.
CHAPTER 5
IN VITRO SCREENING OF NOVEL PLATINUM COMPOUNDS
FOR CLINICAL USE
5.1 Introduction.
The background to the development and current use of the L1210 murine
leukaemia in the screening of novel compounds has been discussed in
Chapter 2. The process of early assessment of potential anticancer drugs
will be addressed in this chapter.
The advantages of using an in vitro system to study the potency of novel
compounds include
i) facilitation of investigation of the biology and chemistry of cancer,
ii) provision of information on the molecular basis of cytotoxicity and
iii) reduced cost compared with in vivo work.
Whereas the L1210 and P388 cell lines have advantages in tissue culture
because of their rapid growth and ease of manipulation, human tumours
established in culture provide improved clinical predictiveness especially
where tumour xenografts can be developed. The rationale is that human
cancer cells in vitro may give a helpful indication of the molecular events
underlying drug toxicity, while studies of the xenografts enables an
understanding of the pharmacological events which will govern drug utility
in the whole animal.
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Although in 1985 the drug screening system of the NCI abandoned its in
vivo tumour panel and adopted in vitro human cancer cell lines [Grever et al,
1 992], the difficulty of converting in vitro data to parameters predictive of
in vivo and clinical activity has not yet been resolved. The fact remains that
many anticancer drugs - for example the platinum IV compound tetraplatin -
were selected for further clinical development principally because of the
activity that they demonstrated against murine tumours, and continued use
of these non-human lines in screening systems is necessary to provide an
essential historical reference in future drug development.
In addition to the L1210 murine leukaemia cell line and its resistant variants,
other tumour models employed to screen the lead platinum compounds are
the mouse plasmacytoma line ADJ/PC6 and human ovarian carcinoma cell
lines. The importance of the ADJ/PC6 as a predictor of the clinical utility of
platinum compounds was demonstrated by its use in the selection for
clinical trials of carboplatin and iproplatin [Harrap, 1985]. An important
feature of these murine cell lines is that they are freely interchangable from
in vitro to in vivo and vice versa, allowing comparison of cytotoxic and
pharmacologic mechanisms as outlined above.
At the Drug Development Section in the Institute of Cancer Research in
Sutton (ICR), compounds which demonstrate activity against both resistant
L1210 cell lines and the ADJ/PC6 in vitro may be tested in mice bearing
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ADJ/PC6 xenografts. Thereafter, their cytotoxic activity against six human
ovarian carcinoma ceil lines is measured. These human ovarian cell lines are
discussed in more detail in Chapter 5.4. They contain examples of tumours
with both intrinsic and aquired resistance to platinum and have previously
been ranked in order of their sensitivity to the four 'calibrating' platinum
drugs cisplatin, tetraplatin, carboplatin and iproplatin (Hills et al, 1 989).
Using the cell lines as described above, several platinum compounds were
screened for their activity as orally administerable drugs with antitumour
activity and toxicity comparable to cisplatin and carboplatin. The
advantages in having an orally delivered anticancer drug include more time
at home for the patient, perhaps improving his quality of life, and less
expensive in-patient treatment which is increasingly important in these cost-
conscious times.
It has already been demonstrated that cisplatin, carboplatin and iproplatin
have moderate antitumour activity after oral administration to mice carrying
the PC6 tumour, but poor absorption necessitated delivery of much larger
drug doses [Siddik et al, 1984; van Hennik et al, 19891. Significantly, oral
administration ameliorated nephrotoxicity.
A compound which is to be absorbed following oral administration should
be neutral and lipophilic since one of the most important pathways for
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absorption is passive diffusion through the small intestine. The search for
a new platinum drug must therefore be guided by a knowledge of the
biochemical advantages conferred by particular structural groups. The
interest aroused by the finding that the diaminocyclohexane (DACH) ligand
conferred activity against L1 210/cisplatin led to eventual clinical evaluation
of compounds incorporating that structure, namely JM82, TN06, oxaiiplatin
and tetraplatin, all of which were reviewed in Chapter 1.4.
The mixed amine compounds of general formula cis-Pt(ll)CI2(NH2R)(NH3)
retain the principal structural features required for activity (cis arrangement
of labile ligands, Pt in the +2 oxidation state) and the unsubstituted amine
ligand serves to stabilise the DNA lesion through hydrogen bonding to the
phosphate backbone of DNA [Sherman et al, 1 985]. Many such compounds
were developed and screened at the ICR for antitumour activity following
oral delivery.
In this chapter, the results of activity and toxicity studies are presented for
a series of six structurally related ammine/amine platinum IV dicarboxylates
(Figure 5.1) which were tested against the L1210 sensitive and resistant
lines in vitro and subsequently the ADJ/PC6 tumour in vivo. The six 'lead'
compounds were then tested against the panel of human ovarian cancer
cells in vitro in order that their activity in a human tumour might be
assessed.
FIGURE 5.1





































































5.2 Materials and methods.
5.2a Estimation of compound cytotoxicity in L1 210 sensitive and resistant
cell lines in vitro.
All cell lines were grown in supplemented RPMI 1640 medium as described
previously. The starting concentration of cells was 5 x 104/ml, thus
ensuring that cells were in the logarithmic growth phase. Test drug at five
different concentrations was added to the cells and incubated at 37°C for
48hours. The cells were then counted on a coulter counter and the IC50
was defined as that drug concentration which reduced the cell growth by
50%.
5.2b Estimation of compound potency against the ADJ/PC6 tumour in vivo.
Balb C mice of equivalent age had a 1 mm3 tumour implanted in the flank on
day 1 of the experiment. On day 20, animals bearing tumours of
comparable size were randomised to receive either drug (3 animals per dose
level) or vehicle only (10 animals). Drug was administered after dissolution
in arachis oil and sonication as a single dose by oral gavage directly into the
stomach or by intraperitoneal (ip) injection. The animals were sacrificed on
day 30 and tumours were dissected out from the treated and control groups
and weighed. The relative effectiveness of each compound was then
calculated through comparison of the therapeutic indices (see below).
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5.2c Therapeutic index calculation.
The therapeutic index of a compound is calculated from a knowledge of its
LD50 and ED90. The LD50 is that dose which proves lethal in 50% of the
mice tested (Weil 1 952). The ED90 represents the dose which is effective
in reducing the tumour mass by 90%. Control mice are those which receive
no drug. The tumour size in control mice is compared with the mean tumour
weight for the three animals treated per dose of drug. The quotient of
LD50/ED90 gives an indication of the relative selectivity of each compound
tested. An increase in the toxicity (lower LD50) with no change in the
drug's antitumour activity (ED90) would therefore result in a lower
therapeutic index (Tl).
5.2d Growth of the ovarian cell lines.
The six ovarian carcinoma cell lines were grown as monolayer cultures. All
except 41M grew in Dulbeco's Modified Eagle's Medium (DMEM)
supplemented with 10% fetal calf serum, 50//g/ml gentamicin, 2.5/yg/ml
amphoteracin B, 2mM glutamine and 10//g/ml insulin with 0.5//g/ml
hydrocortisone as growth factors in a 10% carbon dioxide, 90% air
atmosphere. 41 M cells were grown in a 1:1 mixture of DMEM and Hams
F1 2 medium with the same additives. The lines established from xenografts
(PXN94 and HX62) required control of stromal fibroblast overgrowth through
selective detachment of fibroblasts using a 30 second incubation with
0.02% EDTA and the use of a feeder layer of lethally irradiated Swiss
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mouse embryonic fibroblast 3T3 cells. Cellular contamination with
mycoplasma was excluded by periodic checks using staining with Hoechst
33528 dye and examination under a fluorescent microscope.
5.e Preparation of cells for the Sulforhodamine Assay.
On day 0, each cell line was trypsinised, spun in a Centaur centrifuge at
1000g for 5 minutes and the pellet resuspended in 10ml supplemented
DMEM. Cells were counted using a haemocytometer and resuspended at a
concentration of 2.5 x 104/ml (excepting the 41 M line which was set up at
5 x 1 04/ml). Using a Titertek Multidrop, 200/vl cells were added to each well
of a 96 well plate. Cells were then incubated in a C02 incubator at 37°C
overnight to allow attachment.
The six lead compounds were prepared in solution on day 1. Drugs were
dissolved in ethanol at 2mM (JM221, 272 and 273) or 1mM (JM216, 269
and 274) and serial dilutions were done in 2.5% ethanol, a concentration
known to be non-toxic to the cells. The drug concentration range was
10/vM - 2.5 x 10VM for the first three compounds and 5//M to 2.5 x 104//M
for the latter three because of their lower solubility. Each drug was prepared
at ten concentrations: 0.00025jt/M, 0.001//M, 0.0025//M, 0.01/yM,
0.025//M, 0.1//M, 0.25/yM, 1.0/vM, 5/yM and 10//M.
Drug was added to the wells in quadruplicate using a multipipetter. Control
wells at either end of the plate were treated with 50/vl of 2.5%
ethanol/medium. The treated cells were then incubated for a further 96
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hours.
5.2f The Sulforhodamine Assay.
The medium was decanted and the plates were gently immersed in ice-cold
10% trichloroacetic acid (TCA) and placed on ice for a minimum of 30
minutes. For cell lines prone to detachment (CH1 only), the TCA was
poured off after 30 minutes and replaced with ice-cold methanol for 5
minutes. The fixative was then tipped off and the plates were washed
gently with tap water five times. The plates were then placed inverted on
tissue to dry.
Using the Titertek-Multidrop, 100//I of Sulforhodamine B (0.4% in 1 % acetic
acid) was addad to 11 of the 1 2 rows. This was left for 1 5 minutes then
tipped off and the plates washed 4 times with 1 % Acetic acid. The plates
were again inverted and left to air dry overnight.
The following day, 100//I 10mM Tris (unbuffered) was added to solubilise
protein-bound SRB. The plates were set on a shaker for 5 minutes and their
optical density read at 540nm.
The percentage inhibition of cell growth was then calculated, graphs drawn
and the IC50's calculated.
Sulforhodamine detects the basic amino acids (mainly lysine) as detailed by
Skehan and colleagues [Skehan et al, 1990].
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5.3 Results.
Table 5.1 shows the in vitro cytotoxicity of the ammine/amine dicarboxylate
dichlorides against the sensitive L1210, and L120/cisplatin,
L1 210/tetraplatin and L1 210/carboplatin. Figures in parenthesis represent
the -fold resistance compared with the sensitive line. All of the mixed amine
complexes retain activity against the resistant L1 210 cell lines with JM274
(R = cyclo-C6, R, =C4H9) the most potent - IC50's of 0.05 to 0.08uM.
Table 5.2 compares antitumour activity of oral and intraperitoneal platinum
IV mixed amine complexes against ADJ/PC6 xenografts. Apart from JM221
(R = cyclohexyl, R1 = C3H7) which was less potent when given orally (ED90
ip = 2.5mg/kg and po = 5.2mg/kg), the mixed amine compounds exhibit
similar antitumour activity (ED90) when delivered by either route, but the
LD50 is substantially increased following oral administration consistent with
reduced toxicity (eg.JM274 where R = cyclohexyl, R1=C4H9 has LD50
ip = 14 and po = 1120). The Tl is therefore increased with oral
administration of all six compounds (eg. JM269 where R = cycioheptyi,
Rt = CH3 has Tl ip = 6.1 and po = 269). The data for cisplatin are added for
comparison at the end of the Table 5.2. It can readily be seen that although
there is more potency (low ED90 of 0.6mg/kg) following ip delivery of
cisplatin, oral administration is significantly more toxic (LD50 = 14mg/kg
versusthe lowest of 1 70mg/kg for JM272 where R = cyclohexyl, R^ = (CH3)2)
and there is a large difference in the Tl (6 for cisplatin compared with 59 -
3.
TABLE 5.1
in vitro cytotoxicity of lead ammine/amine dicarboxylate dichlorides against
sensitive and resistant L1210 cell lines.
Compound JM No.
IC50 (//M)
Cell Line 216 221 272 273 274
L1210/S 1.2 0.06 0.14 0.08 0.05
L1210/cis 1.5 0.11 0.1 0.07 0.08
(10) (1.3) (1.8) (0.7) (0.9) (1.6)
L1210/tetra 1.4 0.06 0.07 0.04 0.05
(34) (1.2) (1.0) (0.5) (0.5) (1-0)
L1210/carbo 1.6 0.12 0.21 0.11 0.08
(13.7) (1.3) (1.5) (1.5) (1.4) (1.6)
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LD50 ED90 Tl LD50 ED90 Tl
216 30 6 5 330 5.8 57
221 15.5 2.5 6 280 5.2 54
269 71 . 11.7 6 2690 10.4 269
272 21 2.9 7 170 2.9 59
273 30 5.2 6 670 3.7 181
274 14 5 3 1120 3.6 311
Cisplatin 1 1.3 0.6 19 14 2.4 6
3 animals treated per dose level
10 animals were controls - received vehicle only.
lowest value of all compounds - for JM272).
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Activity of JM21 6, 221, 269, 272, 273 and 274 against six human ovarian
lines in vitro (as measured by the Sulforhodamine assay) is shown in Figures
5.2 to 5.7 with a summary in Table 5.3. The most resistant ovarian
carcinoma cell line in early experiments with 'calibrating' platinum
compounds was SKOV3. In every case the most potent compound was
JM274 (R = cyclohexyl, Rt = C4H9) which had the lowest IC50 concentration
in all six cell lines. JM273 (R = cyclohexyl, R, =(CH3)3) also demonstrated
excellent antitumour activity. The least effective compounds were JM21 6
(R = cyclohexyl, R, =CH3) and JM269 (R = cycloheptyl, R, =CH3).
Figure 5.8 demonstrates the relative sensitivity of the six ovarian cell lines
to the six lead compounds with the most resistant line FIX62 taken as
standard (RS1). In these experiments, CHI was the most sensitive cell line.
Comparison of this graph with that delineating relative sensitivities of the
human ovarian cell lines to the four 'calibrating' platinum drugs (Figure 5.9)
belies the much greater potency of the mixed amine dicarboxylate
compounds. Figure 5.10 compares the IC50's of the six lead compounds
and cisplatin, carboplatin and tetraplatin against the most sensitive ovarian
cell line CF11 and the most resistant line HX62. It is quite clear that the new
compounds are generally much more cytotoxic against the human ovarian
cancer cells in vitro.
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Figure 5.8 Relative sensitivity of ovarian cell lines
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Figure 5.9 Relative sensitivity of ovarian carcinoma celi lines
(with SKOV-3 line = standard 1)
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Figure 5.10 Comparison of cytotoxicity of the six 'lead'
compounds and the 'calibrating' platinum drugs against
the most sensitive (CH1) and resistant (HX62) human
ovarian cancer cell lines.
Cyotoxicity




All of the six platinum IV transdihydroxydichloro-ammine/amine compounds
tested retain activity against all of the L1 210 platinum resistant lines (Table
5.1). This finding was believed to be relevant in the search for a new and
more active platinum based anticancer drug and warranted further
investigation of the compounds in vivo.
In the ADJ/PC6 tests in vivo, the mixed amine dicarboxylates exhibited
comparable antitumour potency when administered either orally or by the
intraperitoneal route (ip), but acute toxicity (LD50) was. substantially reduced
by oral delivery (Table 5.2). In addition, the therapeutic index (LD50/ED90)
was greater when the compounds were given orally because of more
selective antitumour activity shown by a fall in the ED90 and an increase in
LD50.
The six human ovarian cancer cell lines used in experiments detailed in this
thesis are well established in culture systems. OVCAR3 [Hamilton et al,
1983]) and SKOV3 [Fogh et al, 1977] were obtained from the American
Type Culture Collection. 41M was established by AP Wilson at the
Oncology Research Laboratory in Derby City Hospital, UK [Hills et al, 1 989].
CH1, PXN94 and HX62 were established in the tissue culture laboratories
at the ICR in Sutton; CH1 was developed from the ascites of a woman with
ovarian carcinoma and the other two were from human ovarian xenograft
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lines grown in female nude mice. Calibration of all six lines against cisplatin,
tetraplatin, carboplatin and iproplatin has been performed and the cell lines
provide a useful ranking system because of their different sensitivities to
these four drugs [Hills et al, 1989] (Figure 5.9). The resistant patterns of
the cell lines represent both innate and aquired resistance to platinum
chemotherapy.
When the relative sensitivities of the ovarian cell lines to the six lead JM
compounds are plotted (Figure 5.8), in contrast to the plot shown in Figure
5.9 there is very little differential sensitivity. CH1 was again the most
sensitive cell line. The most active compound was JM274 (R = cyclohexyl,
R1=(C4H9) which was 16 times more potent against the CH1 -
IC50 = 0.0016uM - than was JM221 (R = cyclohexyl, R^CgHy) -
IC50 = 0.056uM (Table 5.3). This result suggests that potency is increased
by lengthening the axial ligand (R,).
The compounds JM274 and JM273 vary only in the axial group which is
straight (C4H9) for JM274 and branched (CH3)3) for JM273. In the
experiments on tumour-bearing mice (Table 5.2), the Tl was higher for
JM274 at 311 compared with 181 for JM273. The result was effected
mainly by the reduced toxicity of JM274 (LD50 = 1120mg/kg versus
670mg/kg). The IC50's of these compounds against the human ovarian cell
lines were similar except against 41 M where the results were 0.0078uM
(JM274) and 0.01 7uM (JM273) (Table 5.3).
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The number of carbon atoms in the ring on the R group appeared to be
immaterial since on comparison of the cytotoxicity of JM216
(R = cyclohexyl) with JM269 (R = cycioheptyl) where in both cases the R,
group is a simple methyl (CH3) the IC50's against the ovarian cell lines were
eqivalent (Table 5.3). However in the in vivo experiments the antitumour
activity in ADJ/PC6 tumour-bearing mice demonstrated a clear advantage for
the cyclocycloheptyl compound JM269: The low toxicity following oral
administration (LD50 = 2690mg/kg) contrasted with the result for JM216
(LD50 = 330mg/kg) with the respective Tl's 269 and 57 (Table 5.2). Note
from the data detailed above that the Tl of the cyclohexyl longer axial chain
compound JM274 was comparable to that of JM269 (311).
In summary, these experiments demonstrated optimum cytotoxic activity
with longer chain axial ligands. Equivalent activity was not obtained through
shortening the axial chain and substituting the cyclohexyl group at R for a
cycloheptyl moiety.
In comparing the cytotoxic activity of the six PtIV dicarboxylatedichloro
mixed amine compounds with the established drugs cisplatin, carboplatin
and tetraplatin, very little cross-resistance is seen (Figure 5.10), and these
data along with the potency data from the ADJ/PC6 tumour-bearing mice
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emphasise the need to explore further the novel compounds as orally
delivered anticancer drugs.
In the following chapter, pharmacological testing allows further analysis of
the six "lead" compounds.
CHAPTER 6
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PHARMACOKINETICS AND HAEMATOLOGICAL TOXICITY STUDIES
ON LEAD COMPOUNDS
6.1 Introduction.
The advantages in having a platinum based drug which could be delivered
orally have already been stated. In addition to the practical considerations,
there may be an improvement in the spectrum of activity and in the toxicity
profile of a platinum drug which could be given at low dose for longer
periods of time. Treatment with a 5-day infusion of cisplatin has been
shown to reduce nephrotoxicity without associated diminution of antitumour
activity [Salem et al, 1984]. It has previously been shown that cisplatin and
carboplatin possess moderate antitumour activity against the ADJ/PC6
plasmacytoma when given orally [Siddik et al, 1984]. Nephrotoxicity was
20% with oral administration of cisplatin compared with a 6-fold increase
in blood urea in all animals treated by the intravenous (IV) route. The
reduced nephrotoxicity may have been related to the fact that these drugs
are poorly absorbed when they are delivered by the oral route.
In the previous chapter, the screening panels were seen to be effective in
selecting several compounds which showed good antitumour activity against
the sensitive and resistant tumours in vitro and in vivo. The Tl's of the
dichlorodicarboxylate ammine/amine platinum IV complexes (structures
Figure 6.1) measured in the ADJ/PC6 after an oral dose of the
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FIGURE 6.1









































































"dicarboxylates" ranged from 50 to over 300, compared with 6 for cisplatin,
as shown in Chapter 5. The six lead compounds selected from previous
experiments demonstrated good antitumour activity with relatively low
toxicity, therefore it was important to define their pharmacological profiles
and to ascertain their absorption characteristics.
Oral bioavailability is defined as the rate and extent to which an active drug
substance is absorbed and becomes available to the general circulation.
Bioavailability is not, therefore, simply a property of the drug itself but also
depends on the formulation in which the drug is delivered. For a drug to be
bioavailable, it must reach the general circulation intact. The important
difference between absorption and bioavailability becomes apparent when
one considers that a drug, once absorbed, may undergo metabolism or
elimination during its passage through the gastrointestinal (Gl) tract, liver
and lungs. If the drug is subjected to first pass metabolism in any of these
tissues, a portion of the absorbed drug will be lost and consequently less of
the absorbed dose will be "bioavailable". A drug with low bioavailability
which also has a narrow therapeutic range may result in no therapeutic
benefit if there is variability in the oral absorption. Conversely, toxicity may
result should a large proportion of the drug enter the circulation in its active
form [Sietsema, 1989].
Gl absorption is assessed by comparing iv with oral delivery and also by
measuring blood and urine levels after drug administration. The faecal
excretion should also be known since drug recovered in the faeces
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represents the unabsorbed fraction. The enterohepatic circulation is the
system by which the drug is absorbed from the intestine into the liver,
excreted into the bile, and re-excreted into the intestine prior to clearance
either in the faeces or the urine. Delay in faecal excretion beyond 96 hours
may signify extensive enterohepatic circulation of a drug.
In the study of platinum complex absorption, total and free platinum blood
levels are measured. The area under the plasma concentration v. time curve
(AUC) is a measure of plasma platinum concentration variation with time and
enables calculation of the elimination half lives of both total and free
platinum. The total platinum concentration represents the sum of the
protein bound and free platinum whereas the free fraction is the active
platinum.
The pharmacokinetic profile (ie: absorption, distribution, metabolism and
excretion) of a drug characterises and identifies a safe dose for
administration and also defines doses at which toxicities occur. In this
chapter, the mouse model is used to establish the pharmacokinetic profiles
and the haematological toxicity of the six lead dicarboxylate complexes.
Establishment of the murine LD10 dose allows determination of the starting
dose level for human Phase I studies, normally 10% of the mouse LD10.
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6.2 Materials and methods.
6.2a Mice:
Non-tumour bearing female Balb-C mice were used for ali experiments.
Animals were housed in metabolism cages (Jenson Scientific, UK) for 96
hours with free access to food and water. Mice were weighed daily and the
percentage weight loss tabulated. Blood sampling was by the axillary
vessels and was performed under halothane anaesthesia prior to sacrifice by
cervical dislocation.
6.2b Compounds and doses.
Structures of the six test compounds are shown in Figure 6.1. All platinum
compounds were synthesised and donated by the Johnson Matthey
Technology Centre (Sonning Common, UK) and Johnson Matthey
International (USA) as part of a collaborative project. Drugs were suspended
in arachis oil (Sigma,UK) and sonicated briefly (<10 sec at 16 Hz) to
produce a fine suspension for immediate oral administration. Drug
suspensions were delivered to mice by oral gavage using an animal feeding
needle (Poffer and Sons, New York, USA) at a dose of 100umoles/kg
(1 9.5mgPt/kg) in an injection volume of 10ml/kg.
6.2c Identification of LD10.
The oral LD10 (lethal dose in 10% of mice) or maximum tolerated dose
(MTD) of each drug was established using as a guide the initial PC6 data in
tumour-bearing mice (courtesy of P. Goddard). Five female non-tumour
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bearing Balb C mice were treated with one of five doses of each drug as
detailed below:
Compound Doses administered (mg/kg)
JM216 200, 250, 300, 350, 400
JM221 200, 250, 300, 350, 400
JM269 1000, 2000, 3000
JM272 100, 140, 180, 220, 260
JM273 100, 200, 400, 600, 800, 1000, 1200
JM274 400, 600, 800, 1200, 1600
The weight of each mouse was recorded daily over a period of 28 days and
the percentage weight loss recorded. Sick mice were sacrificed and any
particular features thought to contribute to their illness were noted.
The LD10 was estimated as the dose incurring approximately 20% body
weight loss and/or 10% lethality in the mice.
6.2d Pharmacokinetics of orally administered Pt IV dicarboxvlates.
The absorption of the lead ammine/amine platinum IV dicarboxylates was
established in mice through measurement of the plasma levels of total, free
and reversibly bound platinum following equimolar oral doses
(100yt/moles/kg) of each of the six Pt IV complexes. Three mice per time
point were treated with each drug. Blood and plasma collection methods
are described below.
The terminal half lives of the platinum were compared for the compounds
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to enable evaluation of an optimal dosing frequency, with the aim of
maximising activity without incurring unacceptable toxicity.
AUC values (0-24 hours for total platinum and 0-4 hours for "free" platinum)
were determined by the trapezoidal rule. A two compartment model (C = A
exp(-at) + B exp(-bt)) was used to determine the terminal half life of total
platinum and a single compartment model (C = A exp -(at)) for ultrafilterable
platinum. The weighting factor for the curves (estimated by least squares
linear regression) was 1 /(Y + Yhatp2.
6.2e Pharmacokinetics: Blood and plasma collection.
Mice were fasted 18 hours prior to drug administration to optimise the
absorption kinetics and overcome interactions with stomach contents.
Blood sampling was performed at 15', 30', 1, 2, 4, 7, 24, 48, 72 and 96
hours following drug administration.
1.0 ml blood samples were collected in 1.5ml microfuge tubes and spun for
3 minutes at 1000rpm in a Beckman Microfuge (model B) to obtain the
plasma. Plasma was then divided into
a) 50/yl + 100//I water - for analysis of total platinum
b) 25//I + 50//I ice cold methanol; the combined free and reversibly bound
platinum was detected in the soluble fraction following addition of methanol
at 4°C, standing the sample on ice for 10 minutes then spinning it in the
microfuge for 1 minute. The precipitate was discarded.
c) free platinum in the plasma was determined following ultrafiltration in a
Europa centrifuge at 3000rpm, 4°C for 30 minutes using Amicon CF50A
centrifree membrane cones as described by Litterst (Litterst 1976(b)).
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Samples were stored at -20°C until analysis when they were diluted (as
detailed above) and analysed for platinum by flameless atomic absorption
spectrophotometry using a Perkin-Elmer HGA 700 atomic absorption
spectrophotometer.
Results are expressed as //gPt/ml plasma.
6.2f Excretion of platinum.
The excretion of each compound was measured as recovery of platinum in
the faeces and the urine of Balb C female mice. Three mice were treated
with each drug at 100/ymoles/kg (19.5mgPt/kg). Faecal pellets were
collected and weighed at 24 hour intervals. Urine was collected daily in
labelled, pre-weighed microfuge tubes. The metabolism cage was rinsed
daily with 10ml water and the resultant wash was collected in a stoppered
Nunc tube.
6.2q Solubilisation and analysis of faecal samples.
Samples were weighed (each approximately 300mg), placed in 20ml pyrex
pots and 2ml concentrated fuming nitric acid were added to each pot. The
samples were left to digest in a fume cupboard overnight. The nitric acid
was boiled off by placing the pots on a hot metal block and heating at
1 20°C for 1 hour. When 100-200//I remained, 2ml 1.0N Hydrochloric acid
were added and the boiling repeated, after which 2ml 0.1N Hydrochloric
acid were added and boiled off. A further 2ml 0.1 N Hydrochloric acid were
then added and the mixture warmed gently. The contents were pipetted
into 10ml stoppered Nunc tubes. The original pot was washed with 2ml
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0.1N HCI which was decanted into the Nunc tube and made up to a final
volume of 5ml.
The samples were diluted as tabulated below prior to being analysed by
flameless atomic absorption spectrophotometry (FAAS), model IL655:
Sample time Fold dilution Deposition time





Standards were prepared at 196ng Pt/ml (50//I of 10/yg/ml Pt standard to
2.5ml 0.1N HCI) for the 5 second deposition time and 49ng Pt/ml (50/yl of
2.5//g/ml Pt standard to 2.5ml 0.1 HCI) for a deposition time of 25 seconds.
The % dose excreted in faeces was assessed for individual mice.
6.2h Analysis of urinary excretion.
On completion of the experiment the microfuge tubes were reweighed and
the volume of urine was calculated. The volume of the washes was made
up to 10ml with water. Urine samples were diluted as tabulated below prior
to being analysed by FAAS:
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Sample time Fold dilution Deposition time





The 24 hour washes were diluted 1:3 and later washes were measured neat.
Deposition time was 3 seconds in all cases.
Standards were prepared as for the faeces samples (outlined above).
The % dose excreted in urine was assessed for individual animals at each
time point.
6.2i Assessment of haematoloqical toxicity.
The haematological toxicity of each compound was measured in Balb C
female mice following an oral dose of the LD10, 0.5 LD10 and 0.25 LD10.
Three mice were dosed at each level for each of the six drugs, and controls
received oil only or no treatment. All drugs were made up in arachis oil and
administered by oral gavage. Sampling time points were days 1, 2, 4, 7,
10, 14, 21 and 28. Blood samples (0.5ml) were placed in heparinised tubes
and delivered to the Haematology Laboratory, Royal Marsden Hospital,
Sutton for analysis of the full and differential blood count. Results are
expressed as a mean percentage of control cell counts +/- standard error.
The nadir and temporal profile of white cell, haemoglobin and platelet counts
were assessed for all compounds.
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6.3 Results.
Table 6.2 shows the LD10 calculated from the nearest test dose causing
approximately 20% weight loss in 5 mice. For compounds JM216, 221,
272 and 274 the lowest doses tested were closest to the LD10 and final
dose selected for the experiments. The selected dose for JM269 was taken
as the point between 1 g/kg and 2g/kg because of the weight losses of 23%
and 27% (lowest levels) for these two wide-ranging test doses. The LD10
for JM273 in PC6 tumour-bearing mice was around 600mg/kg and initial
experiments in the non-tumour-bearing Balb-C mice initially used this as the
mid dose. However, there was unacceptable toxicity and the experiment
was repeated using 100, 200 and 400mg/kg. The final dose selected as the
LD10 was 150mg/kg.
Figures 6.2 to 6.7 represent plasma concentrations of total and free
platinum in mice following dosing with 100//moles/kg of each test
compound. For each Pt IV dicarboxylate, plasma concentrations are
expressed as /vgPt/ml and plotted against time. The peak plasma levels
occurred very rapidly - between 15 and 60 minutes - with a small second
peak at 4 or 7 hours. These findings are consistent with very rapid
absorption following oral administration. The peak plasma concentrations
were between 1.94//gPt/ml (JM274 R = cyclo-C6, R1=OCOC4H9) and
15.1yC/gPt/ml (JM273 R = cyclo-C6, R, = OCOC(CH3)3).
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TABLE 6.2
Selection of the murine LD10* for lead compounds.
JM no. Body weight**
(% original)
Nearest dose*** LD10
216 75 + /-4 250mg/kg 200
221
I
75 + /-7 200mg/kg 150





272 87 + /-10 100mg/kg 100
273 82 + /-13 200mg/kg 150
274 91+/-4 400mg/kg 400
*
LD10 dose = dose incurring 20% weight loss + /-10% lethality
**
5 mice treated at each dose level
***
5 doses per drug
Figure 6.2 JM216 Total and Free Pt concentration (pg/ml)









Figure 6.3 JM221 Total and Free Pt concentration (JJg/ml)























Figure 6.5 JM272 Total and Free R concentration (pg/ml)








Figure 6.6 JM273 Total and Free Pt concentration (JJg/ml)
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Figure 6.7 JM274 Total and Free Pt concentration (pg/ml)









Table 6.3 summarises the plasma peak platinum concentrations, total and
free platinum versus time concentrations (AUC data) and details the plasma
half life for each of the compounds. JM269 (R =cyclo-C7, R, = CH3) showed
low absorption at the 96 hour time point (1.9/ygPt/ml), as did JM274 with
its long R., straight chain (C4H9) (1.94^/gPt/mI). The highest plasma
concentration was achieved with oral JM221 (R = cyclo-C6, R.,=CI-I3) at
120//gPt/ml/hr and there was also a high free platinum concentration
(3.2/ygPt/ml/hr) at 7 hours after dosing. Interestingly, the plasma half life of
JM221 was second shortest at 18.8 hours for the total yet the free fraction
demonstrated a t1/2 close to that of the other compounds (3.14 minutes).
JM273 was absorbed quite well and the relatively high concentration of free
platinum (1.43yc/gPt/ml/hr) had a remarkably long half life (35.5 minutes)
even although the total platinum was rapidly cleared, demonstrating the
shortest half life at 17.3 hours. JM216 was well absorbed (AUC for total
platinum 108/ygPt/ml/hr) but there was a disproportionately low free
platinum concentration (0.7//gPt/ml/hr).
The faecal excretion data are shown in Table 6.4. At the 24 hour time
point, the faecal excretion of the six compounds ranged from 14-41 %. At
96 hours JM216 and JM269 -which differ on;y in the size of the ring at
cyclo-C6 and cyclo-C7 respectively -had widely differing excretion at 75%
and 53% respectively. Faecal excretion of the other 4 compounds ranged
from 46% to 48% over the same time scale. The small difference in faecal




























































•n=3-6miceperti oint reversiblyboundfractionwas<10%t lplatinum •Areaunderthconcentrationv.timecurv(AUC)m asur dâiP /ml/hour
TABLE 6.4
Recovery of compounds in faeces over 96 hours in mice*
COMPOUND % DOSE DELIVERED













* 3 mice treated with each drug
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suggests that it does not undergo extensive biliary recirculation.
Conversely, the high faecal excretion of JM216 (36% at 24 hours and 75%
at 96 hours) suggests either that it is poorly absorbed when delivered orally
(but see total platinum plasma concentrations above), or that it undergoes
extensive biliary recirculation. The same process would account for the
slow excretion of JM272 (R = cyclo-C6, R, = OCOCH(CH3)2) where the faecal
content increased from a low 14.5% at 24 hours to an average value of
47% after 96 hours.
Table 6.5 details the urinary excretion of each of the six compounds. At 24
hours post administration, the % dose excreted ranged from 5.5-18.2%.
At the 96 hour time-point, platinum excreted in the urine ranged from 9%
(JM274 R = cyclo-C6, R^OCOC^g) to 27% (JM221 R = cyclo-C6,
Rt =OCOCH3). The low urinary excretion of JM274 was suggestive of poor
absorption of the compound following oral administration. This concurs
with the plasma concentration versus time data for JM274 where the AUC
for total platinum was lowest of the six compounds at 48/ygPt/ml/hr. The
high renal excretion of JM221 (27% at 96 hours) indicated that the
compound was well absorbed and this was supported by the plasma
platinum concentration v. time data (AUC highest at 120^/gPt/ml/hr).
JM273 (R = cyclo-C6, R-, = OCOC(CH3)3) showed the second highest AUC for
free platinum (1.43/ygPt/ml/hr; t1/2 35.5 minutes) consistant with its good
absorption pattern - peak plasma concentration 15.1/ygPt/ml and urinary
excretion 20% at 96 hours.
TABLE 6.5










* 3 mice treated with each drug
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Table 6.6 is a summary showing total faecal and urinary excretion of each
compound over the 96 hour study period. JM21 6 was the compound most
completely recovered - 93% after oral dosing. This is despite the plasma
concentration data which demonstrated the half life of JM216 to be
intermediate at 21.7 hours (total Pt). The range of total recoveries of the
other five compounds at 96 hours - from 55% to 75% -suggests that they
are extensively protein bound.
In Table 6.7, the excretion and absorption data for each of the six
compounds is compared with the therapeutic index as previously calculated
from results obtained in the ADJ/PC6 xenografts. The % excreted in the
faeces is calculated for the 48 hour time point. The % absorbed is
calculated as the amount not excreted in the faeces ie: % faecal excretion
subtracted from a total of 100%. The high therapeutic index (311) for
JM274 (R = cyclo-C6, R1=OCOC4H9) is associated with a relatively low
absorption at 55%. The plasma concentration versus time data (AUC) are
listed for the 48 hour time point in this table to relate them to the faecal
excretion over the same time period.
JM269 and JM273 are more interesting compounds when these data are
analysed since they are both well absorbed (>70%) and demonstrate good
antitumour activity with low toxicity (Tl's 269 and 181 respectively).
Table 6.8 is included for easy reference to the antitumour activity of
167
TABLE 6.6
Total recovery of each platinum compound (96 hours)
COMPOUND STRUCTURE % DOSE DELIVERED
(URINE + FAECES)
JM216 R = cyclo C6 Rt = CH3 93
JM221 R = cyclo C6 Rt = C3H7 75
JM269 R = cyclo C7 Rt = CH3 65
JM272 R = cyclo C6 R, =
CH(CH3)2
72
JM273 R = cyclo C6 Rt = (CH3)3 66
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the six compounds following oral delivery to mice bearing the ADJ/PC6
tumour, as discussed in Chapter 5.
Figure 6.8 details in histogram form the change in haemoglobin for each
compound delivered at LD10, 0.5LD10 and 0.25LD10 doses. Results are
expressed as a percentage of the haemoglobin levels in control mice. None
of the six compounds induced a fall below 76% of the pretreatment level at
the nadir point (Day 7).
Figure 6.9 demonstrates the platelet counts for the compounds at the nadir
(Day 10 for all compounds except JM272 - Day 7). Again counts are
expressed as a percentage of those measured in the control group of mice.
Toxicity is expressed according to WHO criteria (WHO 1 979). At the LD10
dose, there was significant (WHO Grade IV) thrombocytopenia after JM221,
JM269, JM273 and JM274. JM216 and JM272 induced Grade III
thrombocytopenia. At the 0.5LD10 dose, Grade II toxicity was seen for all
six compounds, and there was little difference between these levels and
those following the 0.25LD10 dose.
The total white cell count (WCC) at the nadir following delivery of each
compound is shown in Figure 6.10.For all except one of the compounds, the
lowest counts occurred on Day 4. The nadir count for JM274 was seen on
Day 7 after dosing. There was an 80% reduction in WCC, when compared
with control mice, after dosing with five compounds at the LD10 dose. The
exception was JM274 where the result was 43%+/_22. The standard
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Figure 6.10 White Cell Count as % of Control
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deviation on this result is larger than for the other five compounds.
Leucopenia was also moderately severe (from 34 - 64% of control values)
following the 0.25LD10 doses, and it is noteworthy that JM273 and JM274
were equally myelosuppressive at LD10 and 0.25LD10 doses.
Figure 6.11 is a histogram of the neutrophil count for each platinum IV
dicarboxylate on Day 4 when differential counts were at the nadir (Day 7 for
JM274). In all cases there was severe neutropenia at the LD10 dose.
JM221 appeared to induce less neutrophil suppression following 0.5LD10
but the error bars in the analysis preclude accurate comment.
Figures 6.1 2 and 6.13 detail the temporal profile of platelet counts for each
lead compound. Following the LD10 dose, recovery of the platelet count to
> 70% of the control values was seen on Day 1 5 for JM216, JM221 and
JM272. Recovery was delayed in JM273 (80% of pretreatment levels on
Day 29), and JM274 (70% of pretreatment levels on Day 29). Platelet
recovery following dosing with JM269 was very rapid from a low
nadir(around 10% of pretreatment levels) as late as Day 15. For the
majority of compounds the thrombocytopenia was less severe and of much
shorter duration following the 0.5LD10 and 0.25LD10 doses.
Figures 6.14 and 6.15 show recovery of total WCC with time. The nadir
white counts were around Day 10 post treatment with each compound for
all doses tested. There was surprisingly little variation in the degree of
white cell toxicity between LD10 and 0.25 LD10 doses. For all drugs except
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Figure 6.12 Temporal Variation for Platelets
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Figure 6.13 Temporal Variation for Platelets
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Figure 6.14 Temporal Variation for White Cells
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Figure 6.15 Temporal Variation for White Cells
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JM269 and JM273, the white cell count had recovered to 70% of more
than control values by Day 30. The error bars were wide in most of these
experiments, and this explains the finding of the 0.5 LD10 dose being
apparently less toxic than the 0.25 LD10 dose for JM273. Recovery of
white count was most rapid for JM216 and JM273 although there was an
apparent later dip between Days 15 and 30 with JM273.
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6.4 Discussion.
It has been reported that the relatively unstable chemical structure of
cisplatin mitigated against it being useful as an orally administered drug
(Siddik et al, 1 984), and indeed the bioavailability of a given dose was only
25% when administered orally [Harrap et al, 1981]. The more stable
structure of carboplatin might have made it a more suitable candidate for
oral delivery, but studies refuted this [Hennik et al. 1989]. The
bioavailability of carboplatin after an oral dose was estimated to be about
1 5% in mice but < 10% in man. The rapid gastrointestinal (Gl) transit time
in the mouse of orally administered cisplatin and carboplatin may have
contributed to the poor bioavailability (Morgan, SE PhD thesis 1989). It
might be expected that the high therapeutic indices in the ADJ/PC6 tumour-
bearing mice seen following oral administration of the six lead compounds
would correlate with an improvement in absorption and bioavailability. The
increased lipophilicity of the compounds would also be likely to increase
their absorption following oral delivery.
It had previously been estimated that the oral bioavailability of several of the
ammine/amine platinum IV dicarboxylates (PtCI2(OCOR1)2NH3RNH2 where
Ri is aliphatic and R is alicyclic) could be as high as 90% following oral
administration [Harrap et al, 1991]. When comparing the data for cisplatin
and carboplatin with those for the dicarboxylates, it was evident that for the
dicarboxylates the ED90's were similar following either intraperitoneal or oral
dosing, yet toxicity (LD50) was decreased 10-fold.
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The LD10 dose in mice following oral delivery of the comounds varied
greatly for the six alicyclic ammine compounds tested, from 100mg/kg for
JM272 (where = OCOCH2(CH3)2, R = cyclo-C6) to 1.5g/kg for JM269
where =OCOCH3 and R = cyclo-C7 (Table 6.1). The Tl's in PC6 tumour-
bearing mice for these compounds after oral administration (Table 6.7) were
59 and 269 respectively, reflecting the comparatively low toxicity of JM269
compared with JM272. Structural comparisons revealed that the two
cyclohexylamine compounds JM216 (R1=OCOCH3) and JM272
(Rt = OCOCH2(CH3)2) differ only in their axial ligand (Figure 6.1). The
increase in axial chain length conferred an increase in the LD50 and a
reduction in the ED90 for JM272 compared with JM216 whereas the Tl's
for these two drugs were similar (59 and 57).
The relative absorptions of JM216 and JM272 were also compared in an
attempt to explain the differences resulting from the structural changes.
From the urinary/faecal data it was seen that a larger proportion of the
administered dose of JM216 was recovered in the faeces over 24 hours
(36%) than after JM272 (14.5%) (Table 6.3). As previously stated, a high
faecal recovery for a compound suggests that it is relatively poorly
absorbed. Considering the urinary excretion of the two compounds, 21 %
of an oral dose of JM272 was excreted in 48 hours compared with 16% of
the JM216 (Table 6.4). The total platinum AUC for JM216 was slightly
larger than that for JM272 (108 yt/gPt/ml/hour and 83 //gPt/ml/hour
respectively) (Table 6.2). Only when the AUC values for the free platinum
were compared was a large difference found, with JM216 reaching 0.7
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//gPt/ml/hour and JM272 4.0/vgPt/ml/hour and little difference in the half life
(Table 6.2). These figures suggest that much more free and potentially
active platinum was present in plasma after oral administration of JM272
than following JM216, thus explaining the larger urinary recovery of the
former compound. The higher circulating free platinum levels may therefore
reflect the increased potency (low ED90) and increased toxicity (lower
LD50) of this compound compared with JM21 6. It therefore appears that
a longer axial chain length is associated with better absorption of an oral
PtIV dicarboxylate compound.
A reduction in absorption was seen in those compounds with acetato axial
ligands as opposed to a congeraxial ligand. This finding was confirmed by
the cycloheptyl analogue JM269. JM269 was less potent than JM272
(ED90 10.4 v 2.9), with a greater than 15-fold increase in LD50 resulting
in a high Tl (268 v. 59)(Table 6.7). The pharmacokinetic data for JM269
revealed that only 6.7% was excreted in the urine over the first 24 hours
post administration (Table 6.4), with 41 % in the faeces for the same period
(Table 6.3). The AUC of JM269 for total platinum was only 12
^/gPt/ml/hour and for free Pt 0.3 //gPt/ml/hour at 48 hours with the amount
absorbed second lowest of all of the six compounds at 52% (Table 6.6). As
stated above, the structural difference between JM269 and JM216 is only
in the R group - cyclo-C7 for JM269 and cyclo-C6 for JM216. Both
compounds have a methyl (CH3) group at R,. The Tl from the ADJ/PC6
experiments revealed a 5-fold difference between the compounds (269 for
JM269, 57 for JM21 6) due mainly to the very low toxicity of JM269 (LD50
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2690) (Table 6.7). The LD10 data also varied greatly (Table 6.1), calculated
at 200mg/kg for JM21 6 and 1 500mg/kg for JM269. The pharmacokinetic
data revealed better absorption of the cyclo-C7 compound JM269 with less
of the administered dose recovered in the faeces at 96 hours (53% JM269
versus 75% JM216) (Table 6.3) yet higher urinary excretion of JM216
(18% versus 12% for JM269) (Table 6.4). JM216 underwent extensive
enterohepatic circulation as shown by the difference in faecal excretion
between 24 and 96 hours (36% and 75%) (Table 6.4). The total amount
of platinum recovered was 93% (JM216) and 65% (JM269), suggesting
that there was extensive protein binding of the latter compound (Table 6.5).
The peak plasma concentrations also suggested better absorption of JM269
(4.9//gPt/ml versus 1.9^gPt/ml) (Table 6.2). However the plasma drug
concentration/time curve revealed a better AUC for JM216 over 96 hours
(108//gPt/ml/hour versus 59//gPt/ml/hour for JM269) (Table 6.2). There
was a less significant difference between the free platinum AUC -
0.7/ygPt/ml/hour for JM21 6 versus 0.3^gPt/ml/hour for JM269 (Table 6.2).
There was also a small difference in the elimination half lives for the total
platinum - 21.7 hours (JM216) versus 31 hours (JM269) (Table 6.2).
The conclusion from these experiments was that although less of the
JM21 6 was absorbed, it was less protein bound and there was an increased
amount of the free (active) platinum around following the oral dose,
mitigating in favour of the cyclohexyl ring structure.
Oral administration of JM274 (Rt = OCO(CH2)3CH3, R = cyclo-C6) to
ADJ/PC6 tumour-bearing mice resulted in a good Tl of 311 (LD50 11 20 and
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ED90 3.6) consistent with good potency as an antitumour agent and low
toxicity (Table 6.7). The urinary recovery was the poorest of all the
investigated compounds at only 5.5% in the first 24 hours post oral dosing
(Table 6.4). A moderate 33% of the dose was recovered in the faeces at
24 hours (Table 6.3). Despite the encouraging LD50 and ED90, the total
platinum AUC (48 yc/gPt/ml/hr) and free platinum AUC (0.8 //gPt/ml/hr) were
among the lowest for all of the compounds tested, implying with the low
urinary excretion that the compound was poorly absorbed (Table 6.2).
Evaluation of the sister compound JM273 was carried out. Here, although
both compounds have a cyclo-cyclo-C6 group on the amine ligand, the axial
ligand of JM273 is a tertiary butarato (R, = OCOC(CH3)3) as opposed to a
straight chain butyrato ligand (Rt =OCOC4H9) for JM274. The Tl of JM273
(181) was the second best of the six compounds (Table 6.7). Urinary
excretion was 11.4% of the oral dose in the first 24 hours (Table 6.4), and
the peak blood level was 15.1 /ygPt/ml compared with 1.94 //gPt/ml for
JM274 (Table 6.2). The AUC for total platinum from 0-48 hours was 72
//gPt/ml/hour following JM273, a marked improvement on the result of
16//gPt/ml/hr for JM274 (Table 6.6). JM273 demonstrated an AUC (0-7
hours) for free platinum of 1.43 /ygPt/ml/hour and this was also significantly
better than the 0.8 //gPt/ml/hour seen with JM274 (Table 6.6).
It was shown (Table 6.5) that over 96 hours the total urine and faecal
recovery of JM273 was 66% compared with 55% for JM274. The
elimination half life of total platinum was 17.3 hours (JM273) compared
with 44.6 hours for the sister compound JM274 (Table 6.2).
These values were the shortest and longest half lives recorded for the six
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lead compounds and suggest that the straight chain of the group on
JM274 results in poorer absorption and more extensive protein binding of
the compound.
JM221 (R = cyclo-C6, R1=OCOC3H7) differs from JM274 only in the one
extra carbon on the latter's aliphatic chain. There was a large difference in
the Tl (57 versus 311) (Table 6.1) and a notable difference in LD10 in non-
tumour bearing mice (150mg/kg vesus 400mg/kg) (Table 6.1), yet rather
less variation in the % of dose absorbed (41% versus 55%) (Table 6.6).
The most impressive change with lengthening the aliphatic chain was in the
plasma concentration versus time curve, since the AUC for total platinum at
96 hours was the highest for all six compounds at 120//gPt/ml/hour for
JM21 6 and lowest for all compounds at 48//gPt/ml/hour for JM274 (Table
6.2). There was a corresponding difference in the free platinum
(3.2/ygPt/ml/hour JM216 versus 0.8/;g/ml/hour JM274).
The conclusion from these data is that the absorption peaks with an
aliphatic chain of three carbons, but it should be noted that the elimination
half life of the longer chain was prolonged, compatable with increased
protein binding of the long chain compound.
The biphasic elimination half life for the six PtIV dicarboxylates was
expected from the data for the parent platinum compounds cisplatin and
carboplatin [Siddik et al, 1988], and there was a relatively narrow range of
values for all six compounds. The fact that the terminal elimination half
lives for total platinum approach two days (Table 6.2) suggests that all of
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the compounds are extensively protein bound. Elimination of free platinum
is biphasic with a rapid alpha half life of between 20 and 172 minutes and
a long beta half life of greater than 7 hours. These findings are of
importance when it comes to repeat dosing with the compounds, since one
may predict cumulative toxicity when the terminal elimination is greatly
prolonged.
The half life of free carboplatin is in the order of 1 0 to 87 minutes, and that
of cisplatin is around 10 minutes following iv administration. The orally
delivered PtIV dicarboxylates are therfore around in the circulation for a
considerably longer period of time than are the parent platinum II drugs
which are currently in use. Equally, the decay of the free platinum is
monophasic for cisplatin and carboplatin and no platinum was detectable
after 24 hours.
Measurement of the haematological toxicity confirmed that the PtIV
dicarboxylates were all toxic to the bone marrow. Thrombocytopenia was
most significant at LD10 doses of JM221, 269, 273 and 274 (Figure 6.9).
The platelet nadir (around 20% of control values) was on Day 10 for all
compounds except JM272 where it plateaued on Day 7. JM21 6 induced
least severe thrombocytopenia, the nadir reaching just under 60% of the
control. Recovery to at least 60% of control values was seen following the
LD10 dose in every case by day 30 (Figures 6.12 and 6.13).
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Leucopenia was also most evident at the LD10 doses of the drugs
(neutrophils <20% of control values for all compounds excepting JM274),
but total neutrophil counts also fell to less than 40% of controls following
the 0.5LD10 doses. For all drugs except JM274, the white cell nadir was
on Day 4. The nadir post JM274 was on day 7. Neutrophils were severely
suppressed even at 0.25LD10 doses (1 5 to 50% of controls). JM274 was
the most markedly toxic to neutrophils at this dose level but as with the
other compounds the effects were relatively short-lived with recovery by
Day 15 in all cases Figures 6.14 and 6.15).
Anaemia was not a significant toxicity with any of the drugs, all values
remaining at or above 80% of the control values on day 7 (Figure 6.8).
In summary, severe neutropenia on day 4 at LD10 and 0.5LD10 doses and
moderate to severe thrombocytopaenia on day 10 at LD10 doses were seen
after treatment with all drugs. Recovery of the counts after a single
adminisration was complete in every case by Day 28, but it could be
postulated that haematological toxicity may be dose-limiting for the six lead
novel platinum compounds.
Further analysis of the PtIV dicarboxylate compounds proceeded with an
analysis of their emetogenic potential in the ferret and assessment of
nephro- and hepatotoxicity. The data resulted in elimination of several of
the six lead compounds and selection of JM216 as the preparation most




The aims of this thesis were to investigate the mechanisms of resistance to
platinum based chemotherapy and to select a novel agent for administration
by the oral route.
Using the L1210 murine leukaemia and its newly developed platinum
resistant variants as in vitro tumour models, it was established that one of
the means by which the cells become resistant is through a reduction in the
uptake of platinum. There was no evidence of an increase in efflux of
platinum from the cells and this mitigated against the p170 membrane
glycoprotein playing a role in these cells' resistance. Colony assay
experiments demonstrated that resistant L1210 cells were better able to
tolerate increased concentrations of intracellular platinum than were the
parent sensitive cells and it was established in later experiments that there
was indeed less platinated DNA in resistant cells when compared with
sensitive L1210 exposed to equivalent doses of platinum. Glutathione
(GSH) concentrations were measured in both the parent line and in the
resistant L1 210. There was a slight increase in the total GSH concentration
in the L1210/carbo cell line when compared with the sensitive, L1210/cis
and L1 210/tetra lines, but no significant difference in GSH levels was found
after exposing the cell lines to the IC50 concentrations of cisplatin,
carboplatin or tetraplatin. Depletion of intracellular GSH through addition of
buthionine sulphoximine (BSO) to the cell cultures did not confer a return of
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sensitivity to the platinum resistant cells, confirming that GSH does not play
a role in platinum resistance in L1210 cells in vitro.
In order to identify a novel platinum complex suitable for oral administration,
six compounds were tested for antitumour activity against the L1210 parent
and resistant cell lines, and against human ovarian carcinoma cells in vitro.
The ammine/amine platinum IV dicarboxylate compounds were selected on
the basis of their potency in inhibiting growth of the ADJ/PC6 tumour in
vivo. The six lead compounds all exhibited antitumour activity against the
platinum resistant L1210 lines (L1210/cis, L1210/carbo and L1 210/tetra).
Studies of the drugs' effectiveness against six human ovarian carcinoma cell
lines in vitro revealed that intrinsically cisplatin resistant cell lines were
relatively more sensitive to the mixed amine platinum IV dicarboxylates.
Optimal antitumour activity was related to the presence of a cyclohexyl
alicyclic ring on the amine ligand with an axial chain length of 6 or 7
carbons.
The absorption of each compound was established following its oral
administration to non tumour-bearing female Balb-C mice. The plasma
concentration of drug was measured at time points up to 96 hours, with
rate and percentage excretion via the faecal and oral routes also measured
to establish a full pharmacokinetic profile for all six drugs. The compound
JM274 (Figure 7.1) demonstrated a high therapeutic index (311) following
oral delivery to mice bearing the ADJ/PC6 tumour, but it was demonstrated
to have the lowest free (potentially active) platinum in plasma and a high
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percentage of recovery in the faeces, indicative of poor absorption. Since
the toxicity of JM274 was low in the ADJ/PC6 experiments
(LD50 = 1120mg/kg), these initial studies suggested that it may be a
favourable candidate for clinical evaluation. Haematological toxicity testing
showed that neutropenia and thrombocytopenia were evident at days 4 and
10 respectively following treatment with LD10 and 0.5LD10 doses of all
compounds.
Although JM274 looked promising in these preliminary screening studies,
experiments of emetogenicity in the ferret model revealed that JM274
induced unacceptable amounts of vomiting. It was therefore necessary to
compromise on efficacy when selecting the agent for further evaluation in
the clinical setting, and JM216 (structure Figure 7.2) was the candidate
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